psilocybin · Mind Medicine Australia

In our first five years, we have made remarkable progress in growing public awareness of and creating access pathways for Psychedelic-Assisted Therapies in Australia. With the success of our rescheduling applications in early 2023, we are now seeing patients being treated with psilocybin and MDMA-assisted therapies for treatment-resistant depression and PTSD respectively. This is an important and historic moment for these therapies and for mental health treatment in Australia.

The TGA decision provides access to these innovative treatments for Australians suffering from treatment-resistant mental illness and paves the way to treat other illnesses such as addictions, obsessive-compulsive disorder, anorexia, cognitive decline and end-of-life stress in the future. In January 2024, the first patients were treated with psychedelic-assisted therapies in Melbourne, Australia. These were the first psychedelic medicine dosing sessions in clinical settings in 50 years.

Our goal is to build the ecosystem for these treatments in Australia. Everyone meeting the medical criteria should be able to access psychedelic-assisted therapies in medically controlled environments. Please see our key strategic objectives below.

What we have achieved in five years with your support:

Awareness and Knowledge Building

• 250+ webinars, screenings and special events attracting 50,000+ participants

• Facilitating Professor David Nutt’s incredibly successful Australian tour in November 2022, where he presented to public audiences, clinicians and decision makers. This tour included a presentation to over 130 people at the TGA in relation to the rescheduling of MDMA and psilocybin.

• Launch of free online Global Webinar Series where World-leading experts provide illuminating presentations and conversations about the ground-breaking opportunity psychedelic-assisted therapies offer and other related topics.

• Launch of Mind Medicine Australia Podcast series

• Launch of MMA Weekly Meditation Sessions

• Video animation explaining the mental illness epidemic in Australia and the benefits of psilocybin and MDMA-assisted psychotherapy with 80,000+ views

• Created a short documentary, Science vs Stigma, to dispel some of the myths associated with these important medicines with over 29,000+ views

• Over 155,000+ views of Shroom Boom, a light-hearted music video

• Implemented a Board Observership program in conjunction with VMIAC

• Appointed as Member of peak body, Mental Health Australia

• Launch of MMA online shop selling a range of unique merchandise including Australia’s first book of Psychedelic Healing Stories

• Initiated Australia’s first Essential Research poll to gauge the sentiment of the Australian public on the issue of access to psychedelic medicines in medically controlled environments as treatments for key classes of mental illness. 67% agreed that ‘People experiencing terminal illness should have the choice to use psychedelic-assisted therapies to ease end of life distress’.

• Developed summary of all trials taking place in Australia

• Over 705,000+ visits to the Mind Medicine Australia website

• Over 63,000+ followers on our social media channels

• Over 650,000+ views on our YouTube Channel

• Over 11,000+ visits to our e-book about psychedelic-assisted psychotherapies

• Over 47,000+ people in our database incl. over 15,000 health professionals and over 1000 psychiatrists

• 670+ donors with 4000+ donations and 80% returning donations

• 200+ media appearances

• 33+ local Chapters around Australia and New Zealand with 2200+ members and growing

• 55,000+ views to our TGA How-to guide during the 2022 public submission period

• Presented and produced Mind Medicine Australia’s inaugural International Summit on Psychedelic Therapies for Mental Illness in November 2021

• Nearly 1000 people registered for our two-day workshop and Global Summit from every state of Australia and more than 15 other nations

• Over 90,000 views of our Summit sizzle reel

• Over 80,000 visits to the Summit website

• Over 5000 queries received from the Summit website

• 110 virtual breakout rooms

• 32 global leaders in the field presented on a range of topics

• 19 major Corporate partners

• Over 160 Education partners

• 17 Supplier Partners

• 15 Media Partners

• 8 Scholarship winners

• 5 Poster winners

• 1 global 4-day event with massive impact

Patient Access

• Successful submissions made to the TGA to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines), allowing limited access to MDMA and psilocybin-assisted therapies from July 1 2023 via the TGA’s Authorised Prescriber scheme

• Granted an Innovation Patent over an improved method of synthesis of MDMA

• Successfully procured medical grade GMP standard MDMA and psilocybin for import to Australia for use in trials and as part of the TGA’s Authorised Prescriber scheme from July 1 2023. We provide equitable access to GMP quality medicine as an exclusive distributor in Australia for Optimi Health

• In January 2024, the first patients were treated with psychedelic-assisted therapies as part of the Therapeutic Goods Administration’s (TGA) Authorised Prescriber (AP) program in Melbourne, Australia with medicines and training supplied through Mind Medicine Australia. These were the first psychedelic medicine dosing sessions in clinical settings in 50 years.

• Established the Patient Support Fund (PSF). Donations into this fund will provide subsidised treatment for those who otherwise could not afford it

• Collaborating with Health Insurers and Governments to broaden the funding base for these therapies

• Developing a gold standard National Care Program, clinical protocols and standard operating practices for psychedelic-assisted therapies in partnership with leading clinical groups around Australia

Professional Development Program

• Our highly anticipated Certificate in Psychedelic-Assisted Therapies commenced in January 2021 featuring a world class Faculty. By the end of 2024, there will be over 500 qualified therapists including psychiatrists, GPs, physicians, psychologists, psychotherapists counsellors, nurses, social workers, occupational therapists, addiction specialists, paramedics and other allied health professionals.

• Confirmed world-leading facilitators for our Certificate in Psychedelic-Assisted Therapies (CPAT) professional development course

• Engaged Dr Gita Vaid (USA) as the course’s International Course Director and Dr Eli Kotler as the Australian Course Director for our programs from 2023 onwards.

• Described as “the best course of its kind in the world” by Professor David Nutt on ABC Radio National interview (UK)

• Over 1000+ applications received since launch

• Over $434,000 raised for CPAT grants through philanthropy to support those in regional and rural areas and therapists suffering financial hardship. Over 85 grants have been awarded so far.

• Over 183,000+ views of the CPAT highlights sizzle reels. Watch current reel.

• Launch of the Fundamentals in Psychedelic-Assisted Therapies Course with over 480+ participants so far

• Developed a mentoring program for graduates of PAT training, allowing ongoing professional development with global leaders in the field

• Recognition by key peak/membership bodies of our professional development and training programs

• Key university student placement partnerships with University of Melbourne and a major volunteering program established

Research

• Successfully advocated for $15 million to support innovative mental health clinical trials utilising psychedelic-assisted therapies from the Federal Government through the Medical Research Futures Fund

• Supported the launch of Psychedelic-Assisted therapies Research Registry at ANU, which will allow for outcome data to be collected from treatment with PAT around Australia

• Launch of The Monash University Neuromedicines Discovery Centre, initially proposed by MMA and developed over a 2-year period

• 32+ current trials of psilocybin, MDMA, LSD and Ibogaine in Australia and New Zealand.

• Developed a BLOG, significant education resources and partnered with Universities to disseminate these as well as sharing these via our website

• Discussions with key University stakeholders continue

Noteworthy from Media Releases:

• Mind Medicine Australia, Marks 5-Year Milestone with Global Achievements in Psychedelic Therapies

• Psychiatrists give the First Psychedelic Medicine Dosing Sessions in Clinical Settings in 50 Years this Week in Melbourne Australia

• Breaking News: The TGA Announces the Delegate’s Final Decision to Reschedule the Use of Psilocybin and MDMA for Medical Purposes

• An Open Letter to the Prime Minister in November 2022

• TGA Expert Review Findings Support the Therapeutic Use of Medicinal Psychedelics in Treating Mental Health Crisis in October 2021

• Mind Medicine Australia Launched Australia’s First Book of Psychedelic Healing Stories in October 2021

• Monash University announced the establishment of the Neuromedicines Discovery Centre to Focus on Psychedelic-Assisted Therapies for the Treatment of Key Classes of Mental Illness in November 2021

• Mind Medicine Australia hosted Australia’s Inaugural International Summit on Psychedelic Therapies for Mental Illness online in November 2021

• Mind Medicine Australia joined a global coalition launched to secure a rescheduling of psilocybin under the 1971 UN Convention on Psychotropic Substances in January 2022

• New Polling by Mind Medicine Australia Revealed Over 60% of Australians Support Increased Access to Psychedelic Medicines in February 2022

• Mind Medicine Australia Lodged New Applications for the Restricted Medical use of MDMA and Psilocybin Assisted Therapies for Patients with Treatment Resistant Mental Illnesses in March 2022. The full applications can be found here.

The progress we are making in public education was exemplified in several headline media articles including in the Australian Financial Review, The Australian, The Age, Herald Sun, The Saturday Paper and Vogue Australia and media interviews including with Channel Nine, Channel 10, The Project, ABC and numerous other TV and radio stations and online media.

In February 2023 the TGA announced that MMA’s rescheduling applications for MDMA and psilocybin were successful. This decision allows psychiatrists to apply for Authorised Prescriber status to administer psilocybin-assisted therapy for treatment-resistant depression and MDMA-assisted therapy for PTSD.

Our primary focus over the next couple of years will be on facilitating the roll out of psilocybin and MDMA-assisted psychotherapy in light of this regulatory change. We are also interested in novel research in this rapidly emerging field to treat a variety of conditions.

Behind the scenes, we are working closely with key stakeholders to ensure that these therapies will be accessible and affordable to all Australians needing these treatments in medically controlled environments, so that cost and geography doesn’t become a barrier.

In the last five years, we have assembled a comprehensive leadership team with expertise in mental illness including psychology, neuroscience and pharmacology, non-profit development, business practices and networks, public health, events, marketing and educational development.

Mind Medicine Australia is also supported by an outstanding Board, Ambassadors, and an Advisory Panel of over 70 local and international experts in medicine, psychiatry, psychology, pharmacology, research, science more broadly, ethics, law, policy, anthropology, business and therapeutic practices. We have also developed a Lived Experience and Young Leaders Panel.

As we move through 2024, our vision and capacity continue to grow. With these medicines now legally available in Australia on a restricted basis, we turn our focus toward ensuring they are accessible and affordable to all Australians who meet the medical criteria.

We ask for your continued and expanded support so that we can fund the path for psilocybin and MDMA-assisted psychotherapy to help treat the millions experiencing key mental illnesses in Australia. This is personal for every one of us.

As Carl Jung said, “The sole purpose of human existence is to kindle a light in the darkness of mere being.”

With gratitude for your interest and generosity. There has never been a more important time to support innovation in the treatment of mental illness.

Peter Hunt AM and Tania de Jong AM

Tania de Jong AM

LL.B (Hons), GradDipMus

Tania de Jong AM is the co-Founder and Executive Director of Mind Medicine Australia. She regularly presents on psychedelic-assisted therapies, mental health and wellbeing at major conferences and events around the world and to Governments, regulators, clinicians, philanthropists and the general public.

Tania is one of Australia’s most successful female entrepreneurs and innovators developing 6 businesses and 4 charities including Creative Universe, Creativity Australia and With One Voice, Umbrella Foundation, Creative Innovation Global, Pot-Pourri and The Song Room.

Tania was named in the 100 Women of Influence, the 100 Australian Most Influential Entrepreneurs and named as one of the 100 most influential people in psychedelics globally in 2021. Tania’s TED Talk has sparked international interest. Tania has garnered an international reputation as a performer, speaker, entrepreneur and a passionate leader for social change. Her mission is to change the world, one voice at a time!

Peter Hunt AM

B.Com, LL.B

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded one of Australia’s leading investment banking advisory firms, Caliburn Partnership and was Executive Chairman of Greenhill Australia. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.

Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He regularly presents to Governments, regulators, clinicians, philanthropists and the general public on psychedelic-assisted therapies and the legal and ethical frameworks needed to ensure these treatments can be made accessible and affordable. He was the lead author of Mind Medicine Australia’s successful rescheduling applications for MDMA and psilocybin, which made Australia the first country in the world to reschedule these medicines.

He founded Women’s Community Shelters in 2011. Peter is a Director of The Umbrella Foundation. Peter also acts as a pro bono adviser to Creativity Australia. He was formerly Chairman of So They Can, Grameen Australia and Grameen Australia Philippines.

Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

Australia, we did it. The first country to formally recognise psychedelics as medicines. Which of course, is what they were and always have been. The decision to criminalise the use of psychedelics is only a recent memory. However, history paints a different picture with psychoactive plants being used as a healing tool for hundreds, if not thousands, of years.

The Therapeutic Goods Administration (TGA) announced that from July, certain psychedelics will be considered schedule 8 drugs – meaning they’re approved for controlled use when prescribed by a psychiatrist. This comes after a plethora of studies published around the healing potential of psychoactive substances to treat certain mental health conditions. The drugs include MDMA for the treatment of post-traumatic stress disorder (PTSD), and psylocibin for treatment-resistant depression. Whilst the rescheduling took many by surprise, countless advocates who have been laying the groundwork for decades are relieved, including Mind Medicine Australia, who made the successful applications to the TGA.

The momentum for psychedelic therapy has been gaining traction in recent years. The conversation around altered states of consciousness is now loud and proud, and remarkably being well received. Mainstream media is saying that we are a society becoming more progressive. Yet, ancient culture would argue that we are only starting to remember our ancestral past. The scientific data undeniably favours therapeutic use of plant medicine. It seems the typically voiceless plant intelligence, is finally speaking for itself.

It was only in 1968, that use of psychedelics was outlawed by the U.S. federal government. Whilst hippy counterculture was running rampant, use of these drugs, particularly LSD, became closely associated with anti-war demonstrations. Before this time, psychedelic therapy, based on the work by psychiatrists Humphry Osmond and Abram Hoffer, was taking off. It involved a single large dose of LSD alongside psychotherapy. Osmond and Hoffer believed that hallucinogens are helpful therapeutically because of their powerful ability to make patients view their condition from a fresh perspective.

Some 40,000 patients were prescribed one form of LSD therapy as treatment for neurosis between 1950 and 1965. As well as similar psychedelics having promising results for treating depression, PTSD, addiction, OCD, relationship issues and other conditions. During this period over 1,000 scientific papers had been produced and six international conferences were held regarding the research and potential healing effects of hallucinogens.

Research came to a halt throughout the War on Drugs, with many practitioners and researchers having to go underground. The 1990s, however, saw a renewed interest in the field. During this time, Ethnobotanist and psychedelic advocate Terence McKenna published a book called ‘Food of the Gods’. This publication explored humans’ symbiotic relationships with plants and chemicals. He surmised that Homo sapiens’ cognitive leap forward was owed to their discovery of magic mushrooms. This theory was as controversial as McKenna himself.

More recently, the ‘Stoned Ape Theory’ gained a new supporter, mycologist Paul Stamets, who suggests that McKenna was right all along. At Psychedelic Science 2017, Stamets presented “Psilocybin Mushrooms and the Mycology of Consciousness” regarding the theory. He advised that the hypothesis is a plausible answer to an age-old evolutionary riddle. “What is important for you to understand is that there was a sudden doubling of the human brain 200,000 years ago. From an evolutionary point of view, that’s an extraordinary expansion. And there is no explanation for this sudden increase in the human brain” Stamets explained. McKenna’s notion constitutes a “very, very plausible hypothesis for the sudden evolution of Homo sapiens from our primate relatives.”

Even if you believe the stoned ape theory is a bit far-fetched, it does arouse curiosity around humans and our relationship to mind-altering substances. Amanda Feilding of the psychedelic think tank Beckley Foundation states, “The imagery that comes with the psychedelic experience is a theme that runs through ancient art, so I’m sure that psychedelic experience and other techniques, like dancing and music, were used by our early ancestors to enhance consciousness, which then facilitated spirituality, art, and medicine.”

Psychoactive plants have been used by non-Western cultures as sacramental tools throughout millennia. They have shaped the course of various established religions and are still used around the world today as part of religious ceremonies. This is well documented in texts from ancient Greece, and Sanskrit texts that form the Hindu religion. Modern day practice includes the Amazonian use of Ayahuasca, the Native American traditions surrounding the Peyote cactus, and the worldwide use of psychoactive mushrooms such as some indigenous tribes in South America. Not to mention suggestibility of certain Australian Aboriginal tribes’ use of the Duboisia genus, a plant hallucinogen called Pituri.

What most of these cultures have in common is using plant medicine as part of a ceremony – usually led by a shaman. They combine techniques to alter consciousness, such as chanting and drumming, to connect to the spiritual world and induce a dreamlike state. Additionally, the ceremonies are beneficial to their communities, helping them to resist certain trappings of Western culture. These communities are largely associated with lower levels of mental illness than those who are more heavily influenced by alcohol abuse.

Furthermore, it’s not only humans that show a tendency towards inducing altered states of consciousness. Evidence shows that many species of the animal kingdom similarly consume psychoactive plants, both recreationally and medicinally. From cats, cows, reindeer and other mammals to insects and fish being attracted to hallucinogenic plants and fungi.

The rise in mental health conditions around the world has certainly been one of the catalysts for the demand of alternative options. Current treatment for many has failed. As our world gets more complex and complicated, so too does our suffering mental health. With Australia now in the limelight, what does it mean to legalise these drugs for therapeutic use?

In a recent TIME article, Rick Doblin (MAPS’ founder and executive director), commented on the rescheduling in Australia. Doblin explains “Australia’s approval of these drugs may only expedite the approval process in the U.S.” However, despite their decision to make these medicines available to patients, Australian regulators have not approved any medications. Additional adequate training for practitioners must also be undertaken. Doblin says, “The drug is not the treatment – it makes the therapy more effective, but it’s about the therapy.”

Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies (CPAT) features a world-leading Faculty. It gives qualified clinicians the additional skills and awareness they need to facilitate psychedelic-assisted psychotherapies safely and successfully. 240 clinicians have already completed the course with many more to come. New intakes are commencing in July 2023. The 90-hour course includes a 6-day intensive utilising holotropic breathwork for all participants. This provides an effective tool for teaching therapists the power of altered states for their own healing and development. They get the opportunity to “sit” with other therapists and learn how to support the patient through these transformational experiences. It will be imperative to train as many therapists as possible over the coming years to meet the growing demand for these treatments.

An integral part of the psychedelic experience comes from its innately spiritual insights. How will therapists respond to this if they haven’t experienced it themselves or are closed off to a transcendental understanding? Dr Rick Doblin and MMA both agree that it will be important for therapists to take these medicines – resulting in a better understanding of how to integrate these experiences with other therapists in Healthy Persons’ Trials.

We need to handle this next phase with care and respectfully bridge the world of ceremony with that of psychedelic therapy. Many have voiced uncertainties around the manufacturing of these drugs. Typically, in a traditional setting there is extreme variability in dosage, which leads to drastically different experiences. This makes it difficult to measure and deal with effects for researchers and practitioners. How do you carefully create a consistent psychedelic experience? And does that perhaps take some of the magic out of it?

‘Filament Health’ is one of the countless companies trying to make psychedelic therapies more accessible. For individuals who can’t make a trip to South America, the Vancouver based company is pioneering a breakthrough medical grade Ayahuasca pill. However, the challenge now lies in striking a balance between the commercialisation and medicalisation of sacred plants.

There are also questions concerning prior and informed consent from indigenous groups for the project, as well as the allocation of money for delicate and pressing issues such as natural species conservation. On one hand, a pill can provide healing for many suffering in the West. Yet on the other, indigenous intellectual property is being made profitable whilst many remain in poverty. There must be a protocol for pharmaceutical companies respecting and paying back. Why should the West get to benefit all the time?

We need to honour the indigenous roots of the psychedelic movement. As a person who had the privilege to consume Ayahuasca in its traditional setting, I recognise the shaman’s guidance as a pivotal part of the experience. Indigenous knowledge must be incorporated to better understand these medicines and altered states of consciousness. Communities also need to be a safe container and be involved.

Rescheduling psychedelics felt like an impossible hurdle, especially in Australia. Seems the hard work is paying off, but we still have a long way to go. We must create a new paradigm. For these treatments to reach as many of those suffering as possible, we will need to develop a new set of values and skillsets. Many of us got involved in the movement because we see a new way of doing things in the world. How do we continue to push against that? With all these unknowns around how the rollout will unfold, we do know one thing for certain – the rest of the world will be watching.

REFERENCES

A brief history of psychedelic psychiatry | mo costandi (2014) The Guardian. Guardian News and Media. Available at: https://www.theguardian.com/science/neurophilosophy/2014/sep/02/psychedelic-psychiatry (Accessed: February 20, 2023).

Ducharme, J. (2023) The future of MDMA, psilocybin, and psychedelics in the U.S., Time. Time. Available at: https://time.com/6253702/psychedelics-psilocybin-mdma-legalization (Accessed: February 26, 2023).

Holyanova, byM. (2023) Vancouver Company creates World’s first ever ayahuasca pill, Psychedelic Spotlight. Available at: https://psychedelicspotlight.com/vancouver-company-creates-worlds-first-ever-ayahuasca-pill (Accessed: February 15, 2023).

The human brain doubled in power, very suddenly, 200,000 years ago. why? (2022) Big Think. Available at: https://bigthink.com/neuropsych/stoned-ape-return (Accessed: February 20, 2023).

Video: Honoring the indigenous roots of the psychedelic movement (2021) https://www.instagram.com/harvardcswr. Available at: https://cswr.hds.harvard.edu/news/2021/03/18/honoring-indigenous-roots-psychedelic-movement (Accessed: February 12, 2023).

Charlotte McAdam

I am a natural health consultant, globetrotter, music enthusiast and freelance writer specialising in the natural healthcare industry. A psychonaut, who draws from my life story and many experiences with indigenous ceremonies from around the world. I am passionate about the ancient teachings of these medicines and how they can help heal our relationship to ourselves, each other and mother earth.

Man in Nature

In this blog series, we are sharing some of the healing stories from our recent book: Psychedelic Healing Stories from Australia. In this blog, we share the story of Maree and her experiences with psilocybin and LSD.

What led you to seek healing through psychedelic medicine?

I was bored with life.

I had money, a decent business, good friends, good health, a great lifestyle (I lived overseas for ten years) but despite all that, I wasn’t happy. I didn’t feel fulfilled or alive. I felt like life was basically meaningless. It was empty.

As a result, I drank too much alcohol. I smoked cigarettes. I took risks with my life, like racing motorcycles through the mountains of Northern Thailand and taking recreational party drugs. Anything to feel. Anything to feel alive.

I was disconnected from myself, disconnected from the people around me and I was not making the most of my potential as a human being. I was not contributing to society and to life in any meaningful way.

What was your psychedelic experience like?

I’ve had several psychedelic experiences and every single one was incredibly healing.

They showed me that I was totally shut down emotionally. There’s a lot of trauma in my family. Sexual abuse, physical violence, emotional abuse, drug and alcohol use, depression, anxiety, and more. My parents also got divorced when I was seven years old.

All of this led me to feel incredible pain when I was a child.

As a result, I shut down emotionally without realizing it. I totally disconnected from myself. Psychedelics showed me that this was why I wasn’t happy, this was why I wasn’t fulfilled. I’d lost parts of myself, and I needed to get them back. I needed to remember who I am.

That meant I needed to feel all the pain from the past. I need to turn towards my pain instead of turning away. I needed to embrace it and work with it, and in that embrace, I realised that I had the power to liberate myself from it. I had the power to heal.

How have you been able to integrate this experience? How has it contributed to your healing process?

I’m happier than I’ve ever been. More fulfilled and more alive. I rarely drink alcohol anymore, and when I do it’s usually only one glass. I quit cigarettes. I don’t use recreational drugs like I used to. I’ve never been on better terms with my immediate family. We’ve resolved all kinds of things from the past and I feel so much closer to them now. I feel lighter, as though I’ve let go of a massive weight that was on my shoulders.

It’s impossible to put into words how powerful and how positive psychedelics have been for me and my family. I think it’s a tragedy that these substances aren’t more widely available, and I hope that more people can experience what I’ve experienced.

This book will show you the deeply human side of the effect this medicine can have, and give you hope, inspiration, and clarity around what is possible for Australians when we get fair access to these breakthrough medicines.

Healing Stories

What led you to seek healing through psychedelic medicine?

I experienced several traumatic events in my military career, which inevitably lead to moral injury and PTSD. I was experiencing depression, flashbacks, and nightmares, which, regardless of my best efforts seemed like I could not escape. I had tried talk therapy, mindfulness, gratitude, meditation, and other healing practices. I felt hopeless, life was void of joy and meaning. I could no longer see the good in the world or the value in my life. A friend mentioned how psychedelic medicine may help me. It was the only avenue I had not explored. I was nervous and hesitant to use the compounds at first but spent several weeks conducting my own research into the experiences, their benefits, and what conditions would lead to a beneficial experience.

What was your psychedelic experience like?

My first psychedelic experience completely changed my life. I gained a new perspective on myself, my experiences, life, the universe, and I felt a deep sense of connectedness to everything. It has been the single most potent spiritual experience of my life. I had a sense of being held, loved, and supported by the universe as I travelled with the medicine.

Consequent experiences took me deep within myself to directly address my trauma in a gentle way, which allowed me to shift my perspective and integrate the trauma. Not only was I able to explore my consciousness, but I was able to experience deep realisations that immediately and continue to improve my life. My psychedelic journeys have been the most healing, powerful, and spiritual experiences of my entire life.

How have you been able to integrate this experience? How has it contributed to your healing process?

I initially struggled to integrate the realisations I had in my early experiences simply because they were so profound and so mind-expanding. Over time they were integrated seamlessly, along with the insights and realisations I had during more gentle journeys. My psychedelic experiences were the single most important part of my healing process.

I have not experienced depression, nightmares, or any other negative consequence of my trauma to date. I can now look at them with appreciation, as these challenges have only contributed to my overall growth as an individual. Not only have I healed and become a happier person, but I now have a deeper respect for all of life, a relationship with the divine, and an appreciation for all of life’s experiences. I cannot be more grateful for these compounds entering my life.

Joshua Tree

In this blog series, we are sharing some of the healing stories from our recent book: Psychedelic Healing Stories from Australia. In this blog, we share the story of Charlotte and her experiences with psilocybin.

During the summer of 2019, I once again found myself searching for answers. I was visiting Joshua Tree in the United States on a road trip I had planned with friends to see a band tour concert. At that point in my life, I had been experimenting with psychedelics for a while. For the last few years, I spent my time travelling to and from America, using cannabis recreationally. I had flown to Peru the previous year and partook in three separate Ayahuasca sessions. Shortly after, I consumed Peyote in a traditional Native American setting and picked ‘magic mushrooms’ in Australia.

*****

The reason I keep returning to psychedelics is the truly magical healing you receive when you use them at the right time in your life, with the proper ‘set’ and ‘setting.’ Trips, undeniably, do have the potential to go wrong. However, if these medicines are used with intention and respect, they can open people up to incredible insights about themselves and the world around them.

*****

I had been an avid traveller for many years and understood the power of manifestation and synchronicities. Knowing how to use your intuition and creativity are skills well-practiced when you’re a young girl exploring wild, yet potentially dangerous situations in countries, unfamiliar to your own. During my many explorations in America, I met and became very close to a group of friends. These people ended up playing a central role in my life and personal growth.

They travelled with me on this adventure, and we got to talking about our life experiences. We shared vulnerable parts of ourselves, which was therapeutic in itself. One of the women and I both suffered from anxiety and negative self-beliefs, which manifested in different health conditions. I developed an eating disorder and my friend developed trichotillomania (see Glossary). For many people with these disorders, it is a way of dealing with negative or uncomfortable feelings, such as stress, anxiety, tension, boredom, loneliness, fatigue, or frustration.

For as long as I can remember, I’ve suffered from some sort of mental health struggle. It started when I was in primary school, where I dealt with depression and anxiety because of an undiagnosed mental disorder. Feeling hopeless and alone, I developed an eating disorder, which then was followed by extremely low self-esteem and self-worth. I noticed patterns of addiction with other substances, but nothing compared to the high of a binge and purge cycle. I had very little confidence by the time I turned eighteen.

Eating disorders and trichotillomania are extremely difficult conditions to treat. Both of us had tried psychiatric medications and talk therapy which helped, but just like most recovery journeys, we found ourselves reverting back to our dysfunctional behaviours.

During this trip, we consumed a North American species of magic mushrooms. The experience was wonderful and insightful. We laughed and cried, but more importantly, we all started questioning our automatic behaviours. We spoke deeply about our body image and felt like we strengthened our relationship with ourselves, each other, and we deepened our connection with nature.

We all reported similar feelings of self-love. Instead of knowing we are worthy of love, we actually felt worthy of love and held the memory of that sense in our bodies long after the experience. We bonded over music and played tracks that helped guide our trip. Because I have researched and had many experiences with these medicines, I understood the importance of doing them correctly. We felt safe in our environment and with each other to be able to explore our inner psyches.

As a result, I better understood the impact that my inner turmoil has on my physical body. Since a major component of eating disorders is the control and restrict aspect, I was able to clearly see how damaging black and white thinking can be. That insight, coupled with a deeper admiration for nature as a result of the psychedelics, has improved how I eat. I now eat more consciously, instead of punishing myself if I eat the ‘wrong’ thing.

This experience in Joshua Tree had positive long-lasting effects on my life, as well as the lives of the other women in our group. It created a profound connection between us that I can reflect on when I start to feel my disorder symptoms returning.

Psychedelic medicines have the potential to help such a variety of mental conditions, that it’s practically criminal to not allow them to be used in a clinical setting. In saying that, psychedelics are not a ‘cure all’ — they are a crash course that can speed up recovery, which is desperately needed for those whose mental illnesses are potentially life threatening.

Integration is just as important as the experience itself. We are all in need of healing in some capacity, it is a part of being human, no one’s life is perfect. However, healing is a journey, and psychedelics with proper integration are powerful medicines that can help us lead healthier and happier lives.

Mental health

Few measures better reveal the character of society than its approach to those who suffer.

Occasionally, the suffering we encounter is beyond our capacity to relieve. In those cases, we can be held to no higher standard than that we have responded with care and compassion. However, what is to be said of a society that could have offered relief – yet refused to do so? How might such a society be judged? Will history excuse those who plead ignorance, or prejudice, or a lack of moral courage to do what was not only possible but necessary? I think not.

Such is the case in our society’s response to those who suffer from mental illness yet are denied access to the increasingly proven benefits of psychedelically assisted clinical therapies. Too often, those who suffer have already given all in service of their society: military personnel, first responders who too often suffer from Post-Traumatic Stress Disorder (PTSD). Can we justify the continuing harm done to such people when we know that, in many cases, effective treatment options are locked away for no good reason? I think not.

Mind Medicine Australia begins and ends with scientific evidence.

The world abandoned prospective treatments not because they were unsafe or ineffective but because they were associated with the ‘wrong’ side of politics. So, what politics abandoned, let ethics restore. Let us not be a society condemned for the suffering we might have prevented – if only we had made better choices, for a better world.

Dr Simon Longstaff AO is Executive Director of The Ethics Centre and a Director of Mind Medicine Australia.

Dr Simon Longstaff AO

B.Ed., Ph.D

Dr Simon Longstaff commenced his work as the first Executive Director of The Ethics Centre in 1991. He undertook postgraduate studies in Philosophy as a Member of Magdalene College, Cambridge.

Simon is a Fellow of CPA Australia and in June 2016, was appointed an Honorary Professor at the Australian National University – based at the National Centre for Indigenous Studies. Formerly serving as the inaugural President of The Australian Association for Professional & Applied Ethics, Simon serves on a number of boards and committees across a broad spectrum of activities. He was formerly a Fellow of the World Economic Forum.

Simon’s distinguished career includes being named as one of AFR Boss’ True Leaders for the 21st century. In 2013 Dr Longstaff was made an officer of the Order of Australia (AO) for “distinguished service to the community through the promotion of ethical standards in governance and business, to improving corporate responsibility, and to philosophy.”

(As published in The Daily Telegraph on 16th February 2022)

The painful COVID-era will fade but it will never be forgotten. This unanticipated period will be remembered for many things – death, suffering, economic and social disruptions and words like lockdown, iso, quarantine, social distancing, Zoom, omicron…

But beyond changes in the way we live and communicate, it is the devastating toll on our mental health that will continue for generations to come. Depression, anxiety, trauma, suicide, addiction, loss of livelihoods, domestic violence and broken families are increasing. We have never felt more isolated, alone and uncertain about our futures.

Our families and communities are suffering, and we urgently need access to preventative and curative medicines and medical care that is safe and effective.

Mental health charity Mind Medicine Australia recently commissioned Essential Research to conduct a representative opinion poll of more than 1,000 Australians. It found that only a small minority was aware of the immense promise of psychedelic-assisted therapies, with just 11% of those asked aware of the medicinal properties of these substances and their potential use in controlled settings. This is despite over 160 recent studies by some of the most prestigious research institutions – Johns Hopkins University, Imperial College London, Oxford, Yale to name but a few – clearly showing the quantifiably positive impacts that these substances can have when used as medicines in combination with therapy, under the guidance of trained doctors and therapists in a clinical environment.

These ground-breaking treatments offer therapeutic access to either psilocybin (the active ingredient in ‘magic mushrooms’) or MDMA, a synthetic medicine. These therapies have been scientifically proven to be safe, non-addictive and effective cures for depression, trauma, end-of-life anxiety and addictions after a short treatment program. Remission rates range between 60-80% with no serious adverse events.

Both medicines have been granted Breakthrough Therapy Status by the Food and Drug Administration (FDA) in the United States to fast-track their approval. This designation is only given to medicines that may prove to be vastly superior to existing treatments.

Although the recent poll showed that only one in nine Australians was aware of these impacts, when they were informed about the results of recent studies, their views changed dramatically towards supporting access to these promising medicines that remain illegal under Australian law. 67% agreed that ‘People experiencing terminal illness should have the choice to use psychedelic-assisted therapies to ease end of life distress’, 63% agreed ‘People experiencing mental illness should have the choice to access them in medically-controlled environments and as an alternative option for treatment-resistant patients’’, and 60% agreed ‘The difference between medical and recreational use of psychedelic substances should be legislatively recognised’.

Trials are underway in Australia and the demand for these therapies is accelerating rapidly. As ever more legal jurisdictions legalise, decriminalise or otherwise tolerate these substances – Oregon, Washington DC, Jamaica, Canada, the Netherlands and elsewhere – support will grow further. Given our publicly funded health care system, mental health epidemic and human right to access to all forms of safe and effective medicine, huge majorities rightly believe that people should not be prevented from legally accessing medicines in therapeutic settings that can help them in ways that no other pre-existing medicines can.

An official decision by the Therapeutic Goods Authority last year refused to reschedule both psilocybin and MDMA as Controlled Medicines (Schedule 8). This rescheduling would make it easier for doctors to access these therapies in clinical environments for treatment-resistant patients through our Special Access pathways. If these legislative changes continue to be delayed, many more desperate people will seek the treatments underground. Everyone deserves the chance to get well.

A new international campaign on the Right to Universal Access to Safe and Effective Medicine is now underway seeking support for a declaration to this effect, while another initiative is seeking the international rescheduling of psilocybin under the UN drug control regime. There is a growing global movement and a trillion dollar market is emerging. Continuing the status quo not only makes little sense in terms of public health but it is also cruel. There is increasing awareness that help is available, yet these treatments are being withheld even though existing medicines don’t work for the majority.

Arguably, continuing to deny access to these medicines is also a clear human rights violation. Refusing and making illegal therapeutic access to safe medicines with a proven effect violates a whole range of internationally recognised human rights, including the right to the highest attainable level of physical and mental health, the right to access all forms of safe and effective medicines, the right to access pain medication, the right to dignity of the human person, and even the right to be free from inhumane, cruel or degrading treatment or punishment.

The COVID-19 pandemic has reminded us that we all deserve access to high quality treatment. As the pandemic becomes endemic, let’s turn our collective minds to ensuring that everyone everywhere has access to each safe and effective medicine. Medicines that are non-addictive, non-toxic, voluntarily taken, administered by trained medical professionals and implemented lawfully, without the threat of sanction for either the patient or the doctor involved.

This issue is not only relevant to conservative, progressive or ecological voters. It is personal because an estimated 50% of us will experience a mental illness in our lifetime. The people are ready and support change. It’s time for the politicians, political parties and all our Governments to follow suit and act with urgency to avoid further avoidable suffering and suicide.

Scott Leckie

Scott A. Leckie is an international Human Rights lawyer, Law Professor and Director and Founder of Displacement Solutions, an NGO dedicated to resolving cases of forced displacement throughout the world, in particular displacement caused by climate change. He also founded and directs Oneness World Foundation (www.onenessworld.org), a think tank exploring questions of world-centric political evolution and new forms of global governance.

He hosts Jointly Venturing, a podcast dedicated to the question of world citizenship, and manages the One House, One Family initiative, an ongoing project in Bangladesh building homes for climate displaced families. He regularly advises a number of United Nations agencies and conceived of and was the driving force behind more than 100 international human rights legal and other normative standards, including UN resolutions – most recently the Peninsula Principles on Climate Displacement Within States. He has written 22 books and over 250 major articles and reports.

Tania de Jong AM

LL.B (Hons), GradDipMus

In this blog series, we are sharing some of the healing stories from our recent book: Psychedelic Healing Stories from Australia. In this blog, we share the story of Daniel, 39 y.o. Student (Mental Health/Addiction Studies) and his experiences with DMT and Psilocybin.

What led you to seek healing through psychedelic medicine?

The suicide of both of my parents twenty years apart led me to suicidal ideations, depression, and anxiety. With children of my own, I wanted to leave no stone unturned in trying to heal myself. Psychedelics were the last stop before I would finally check out. Luckily, they changed my life.

What was your psychedelic experience like?

Two experiences stand out.

The first was a spiritual awakening using DMT, where I discovered two distinctly different voices in my head. One was full of fear and the need to try to control the experience; the other was my true self, the part of me that’s infinite. The next day in looking for a self-help book, I discovered Eckhart Tolle’s The Power of Now, which explained in the intro, exactly what I had experienced. The voice in my head that wants and fears was not the real me, but my ego.

The second experience was on psilocybin, where my intent was to heal my anxiety. Very soon after ingesting the mushrooms, I felt like my son and I were drowning. This obviously invoked a strong fear response. The hallucination was so vivid that it spanned across multiple senses. I could actually taste the freshwater. Then one by one the experience showed me everything in my life that caused me anxiety. Somehow, I was able to see the underlying pattern that links all my anxiety triggers, and I could trace them to one source, one thought. My father’s suicide when I was just a boy had left a deep-seated subconscious belief that ‘I’m not good enough.’

How have you been able to integrate this experience? How has it contributed to your healing process?

Discovering the infinite part of myself changed my life completely. To roughly quote Eckart Toll, “What a liberation to know that you are not your thoughts.”

My thoughts were toxic drops that were poisoning my entire outlook on life. Depression, anxiety, and suicidal ideations are mostly derived from thoughts, and I was finally free, after decades of suffering.

Papercut head

By Kevin Ke

On September 30th 2021, the Therapeutic Goods Administration (TGA) of Australia published an eagerly awaited report on the use of psychedelics in treating mental health conditions. It is an independent review of the evidence surrounding two particular substances: MDMA and psilocybin, commissioned by the regulatory agency in order to inform its decision making process towards these substances. Currently, these substances are placed in ‘Schedule 9’ of the ‘Poisons Standard’ – the most restrictive classification which includes other substances like heroin. The TGA is in the midst of evaluating a proposal to move them into ‘Schedule 8’, a less restrictive category. Schedule 9 substances are considered ‘Prohibited substances with high potential for abuse and misuse’, and are only accessible for purposes of medical research, in order to severely limit access. Although we are in a time of increasing awareness and interest in psychedelic substances, the history of psychedelic research in the modern era is complex. The current restrictions on psychedelic use for recreational and medical purposes are closely intertwined with US government anxieties about counterculture movements in the Vietnam War era.

The proposal to reschedule is led by an Australian nonprofit, Mind Medicine Australia (MMA), and has the support of world leading experts in psychedelic research. If successful, it will lead to a situation where Australian patients suffering from mental illness can access psychedelic substances for use in therapy. There are no proposed changes to the status of recreational use of psychedelics, which will remain in Schedule 9. A range of safeguards will be in place – for example, prescription will be restricted to being prescribed by psychiatrist or specialist addiction physician. MMA has been training cohorts of qualified psychotherapists specifically in psychedelic-assisted therapies in anticipation of future demand. Access is envisioned to occur in a medically controlled environment with the patient never taking the substances home. As unregistered medicines, prescribers will still require approval on a per patient basis from both the TGA (under Special Access Scheme B) and the State or Territory Government where the treatment is to occur. Mental health conditions like post-traumatic stress disorder (PTSD) and depression are frustratingly difficult to treat, with debilitating impacts on patient’s lives and those around them – and it is envisioned that these patients stand to benefit from a psychedelic experience given in a controlled and supervised setting.

What’s the evidence for psychedelic-assisted therapies?

In recent years, psychedelic research has reached an inflection point, with accelerating recognition worldwide of its therapeutic value in a range of mental health conditions. A landmark phase 3 trial evaluating MDMA for the treatment of PTSD read out earlier this year, sponsored by the pioneering US based nonprofit MAPS. A total of 91 patients with severe PTSD were randomised to two groups, with the average patient having carried the diagnosis for 14 years. A large majority (92%) of patients had experienced suicidal ideation during their lifetime, and 1 in 3 had attempted suicide in the past.

Both groups received a structured program of therapy over 18 weeks, but only one group received MDMA across three sessions, with the other receiving an inactive placebo in its place. The group that had received MDMA-assisted therapy responded considerably better than the group without – with 67% (28/42) of patients no longer meeting the criteria for PTSD diagnosis, compared to 32% (12/37) in the therapy-only group, as measured 18 weeks after initiation of treatment. In a patient group with such severe and intractable disease, these results are remarkable – clearly demonstrating the potential of psychedelic assisted therapy to heal patients who may otherwise never respond to conventional treatment regimes.

How does psychedelic assisted therapy work?

The experience of increased empathy and connection appear to be central to the way that MDMA seems to produce these results. Pharmacologically, the drug increases levels of serotonin in the brain, also acting to increase noradrenaline and dopamine to lesser degrees. Modulation of serotonin neurotransmission is the primary proposed mechanism by which both MDMA and psilocybin are able exert psychological effects. On one hand, an increased level of serotonin binding to the 5HT-1A receptor is thought to lower anxiety, while action on the 5HT-2A receptor increases neuroplasticity and the capacity for learning. In this state of lowered barriers and heightened flexibility of thinking, the individual is able to confront and reprocess their trauma with the assistance of their therapist. Unlike MDMA, psilocybin is a ‘classic psychedelic’ as it predominantly acts on the 5HT-2A receptor like LSD, DMT and mescaline. Experiences of psilocybin have been demonstrated to be effective for conditions like depression, even when the patients are resistant to other therapies. When 5HT-2A receptor activation increases, patients enter into a state of cognitive flexibility and creative thinking where enduring patterns of thought are able to be rewired. Individuals often rank it as among the most challenging and meaningful experiences of their lives – undergoing intense emotional realisations which persist long after the therapy has ended. In this way, psychedelics represent a different approach to treating conditions characterised by fixed mindsets and beliefs like depression and anxiety. Treatment is considerably shorter in duration (a few sessions), and may have more durable results than other treatment modalities. This is quite significant because conventional antidepressants and psychotherapy are known to take several weeks to months to achieve effect, requiring considerable resources. Psychedelics therefore represent a novel modality with distinct therapeutic benefits.

According to proponents of psychedelic assisted therapy, the therapy itself is a crucial part of healing. Also, it is emphasised that the substances are medical grade, produced to purity and stability specification – reducing risks of contamination and adulteration. Theoretical risks that arise from overdose or drug interactions can further be mitigated when given in a supervised setting. While the history of psychedelic research is intricately linked to diverse fields including psychoanalysis, consciousness, religion, and anthropology, the current movement is seeking first to focus on the medical applications, and this stands to reason. It has been reported that the growing acceptance of recreational cannabis use stems largely from its recent medicalisation, with cannabis being explored for a range of diverse applications ranging from anxiety and stress to autism and seizures. In medical cannabis, the TGA also has an important precedent for psychedelic regulation. In February this year, low doses of cannabidiol (the non psychoactive component of cannabis), were rescheduled to Schedule 3, the category for over the counter sale. In practice, it will be some time before pharmaceutical companies achieve registration of their medicines – requiring demonstration of efficacy and safety through clinical trials, a process that can take years. Nonetheless, similar arguments can be drawn between ‘psychedelics’ and medical cannabis, and the shifting tide of public opinion towards this group of substances is also self-reinforcing.

An independent expert review

The original TGA submission from MMA dates back to July 2020, and from there, the original decision of the regulatory agency was to retain the status quo and to not reschedule. Some groups have a different perspective of the benefits and risks of this psychedelic assisted therapy. Medical bodies like the Australian Medical Association and the Royal Australian and New Zealand College of Psychiatrists emphasised a need for clinical trial processes, including careful assessment of efficacy and safety, under strict protocols and ethical oversight. For these groups, psychedelic research is still in its infancy, with ‘limited but emerging evidence that psychedelic therapies may have therapeutic benefit’, and emphasis is placed on their status as illicit substances. The initial decision was challenged by MMA, prompting an independent review of the evidence, bringing us to the recent report.

The expert panel was tasked with reviewing the available evidence on MDMA and psilocybin for the treatment of mental health conditions. Benefits and risks, therapeutic value, and applicability to the Australian healthcare system, were all aspects that were considered. For MDMA, a total of 8 randomised controlled studies were found to be relevant and pooled together, and their results analysed. The rationale is that looking at the results in totality may provide us with better estimates than looking at these studies individually. Results are collated and compared using the statistical quantity ‘standardised mean difference’, or ‘effect size’ – calculated by taking the difference in mean severity scores between groups relative to the standard deviation in these scores. This can be helpful when a range of different severity scores are used between trials, as ‘effect size’ allows for comparisons between different disease scoring systems. However, comparing interventions indirectly through looking only at ‘effect size’ can also be misleading, as different trials inevitably recruit patient populations which are heterogenous or homogenous in their own ways. Trials involving more homogenous patient populations will inevitably have higher effect sizes, while the converse is also true, with all else being equal. With that said, in our report, MDMA assisted therapy was found to have an effect size of -0.86 compared against the control arms, considered generally as a large effect size (almost one standard deviation). This is a promising result considering that the controls also received placebo medication, and the same course of intensive psychotherapy. In other words, patients will experience a large benefit from this treatment, beyond what you might expect from psychotherapy alone. The importance of these results are highlighted when we consider that the only two FDA-approved drugs for PTSD are the SSRI drugs sertraline and paroxetine, which both have modest efficacy, being 2-3 times less effective than MDMA, when compared using absolute change in the CAPS-2 score (and effect size). For psilocybin, six studies were identified by the panel as relevant to their evaluation. Their main findings were that psilocybin was better than placebo for treatment resistant depression, and that it showed efficacy for treatment of anxiety. It was also compared to escitalopram, a common antidepressant – and no ‘statistically significant’ differences were observed, although there is a good argument to be made that this is due to limited statistical power. A closer, critical read of an important recent trial comparing psilocybin with escitalopram would be worthwhile for any interested reader, as the data itself is promising (additional data is in the article appendix). The authors of our TGA report conclude: “MDMA and psilocybin may show potential as therapeutic agents in highly selected populations when administered in closely supervised settings and with intensive support. Evidence appears strongest for MDMA.”

The case for psychedelic assisted therapy is strong, and the high quality evidence which has been generated to date cannot be ignored for long. The recent independent review highlights the clinical efficacy of this treatment, and the TGA is well placed to enact regulatory changes that will encourage the development of the field. In the midst of our current mental health crisis, patients with intractable conditions stand to benefit considerably from a rescheduling of these medicines.

In the lucky country we like to think of ourselves as free, prosperous and privileged. But is our luck running out and what might we do to get it back? Australia is now ranked as the OECD’s worst performer on tackling climate change, our vaccination rollout has by every measure been a dismal failure with Australia today ranked 113th in vaccinating its people, and we are now the nation with the second worst mental health statistics in the world, with only Iceland behind us. Something is clearly not right.

Somehow, we have created a society which promotes the consumption of all forms of alcohol, and where gambling is an addictive source of government revenue. Yet fungi that possess incredible medicinal powers and grows all by itself can, if consumed, put you behind bars.

We allow Australians to drink and smoke, eat ever-growing amounts of sugar, trans-fats and processed foods, causing an obesity epidemic of massive proportions that costs society billions of dollars a year. Doctors easily dole out anti-depressants and pain-killing opiates. Only an estimated 30-35% of depressed individuals in the general population experience remission from current pharmacotherapies or psychotherapies, with the majority experiencing ongoing symptoms, and significant side effects, and between 50% to 80% relapsing after treatment stop. To create positive change and healing, we need to be innovative and broaden the tools available to our medical practitioners and qualified therapists working in this area.

And how free are we if we don’t have access to all of the safe and effective medicines that could cure us when we are ill?

History, science and increasing amounts of data, now clearly demonstrate the enormous potential social benefits of psilocybin mushrooms (psilocybin is the psychoactive component in magic mushrooms) to our mental health, creativity and productivity. Yet digestion of psilocybin remains illegal in Australia, both for medical and recreational uses. Why do prevailing State laws make it illegal to eat completely safe, non-addictive, non-toxic and free wild mushrooms, which may just be growing right outside your door in this magic mushroom season? And yet it is perfectly legal to pick a poisonous mushroom growing nearby that may possibly kill you!

Far from making us ‘lose our minds’, it turns out that the educated, careful and responsible consumption of psilocybin mushrooms might just make us better and healthier people. And yet our minds, the cornerstone of everything we do in this short and finite life, are not as free as we may think.

There is nothing particularly radical or new about humans picking and consuming mushrooms, even those with psychoactive properties. Indeed, we would be hard pressed to find a single human culture anywhere, throughout thousands of years of recorded human history, that did not revere and use these medicinal sacraments to heal a variety of physical and mental ailments. Indeed, many now believe that the original story of our beloved Santa Claus is thought to have come from Nordic indigenous peoples who, along with their reindeer, were known to have regularly consumed the famous Amanita Muscaria mushrooms. Their white dots against a red-capped mushroom dome became the key colours of Christmas cheer.

Though these mushrooms may have a reputation as daunting and dangerous, the science clearly shows that the individual and social dangers associated with the taking of psilocybin is far safer than almost all other drugs, even in recreational environments.

In scores of medical trials of these therapies at the world’s most prestigious Universities including Yale, Harvard, Oxford, Imperial and Johns Hopkins we are seeing remission rates of 60-80% amongst thousands of patients suffering with depression, anxiety, addictions and end-of-life distress. These results occur after just two to three medicinal doses in clinical settings, combined with a short course of psychotherapy. They have been shown to be effective, safe and non-addictive. Many patients describe the therapy as one of the top five most meaningful experiences in their lives! Whoever says that about any medicine?

These outcomes are so promising that psilocybin-assisted therapies are now being studied for the treatment of anorexia and other eating disorders, a range of addictions, obsessive compulsive disorder, dementia, Parkinson’s disease and cluster headaches. The therapeutic use of mushrooms has been legalised in Canada and the U.S. State of Oregon, and compassionate access to these treatments for treatment-resistant patients is being granted in the USA, Switzerland, Israel, and even Australia.

Aside from the realm of mental health, mushrooms are known to fundamentally change things for the better. The pioneering work of globally well-known mushroom experts, including American Paul Stamets, demonstrates that mycelial networks from which mushrooms grow constitute a significant portion of the world’s precious topsoil. They are the neural pathways by which trees and other plants actually communicate with one another. These infinitely complex networks also have qualities that can detoxify waste and greatly enhance the strength and resilience of topsoil. Clearly, mushrooms can do extraordinary things!

Psilocybin mushrooms can intensely reconnect one’s mind and significantly alter consciousness in ways almost impossible to describe to those who have not had this experience. Psilocybin binds to a serotonin receptor called 5-HT2a and takes the brain into a state where it can flow more freely, unconstrained by prior and rigid beliefs about how the world is supposed to work. Psilocybin works through cracking open complexes of suffering contained within the body and brain. It is often said of conventional antidepressants that they merely ‘plaster over’ the root causes of suffering, whereas the defining property of psychedelic therapy is the ability to accelerate self-understanding through revelation leading to complete remission for many.

How can ingesting a mushroom that grows naturally all over Australia still be illegal? In a country that is ‘free’, how can picking a magic mushroom in your garden leave you subject to prosecution and imprisonment? Increasingly, with compassionate motivations, we allow people to use drugs to end their lives via euthanasia, yet we prevent the management of mental illness with a safe and effective medicine that could assist millions to overcome a whole range of health challenges.

As Covid-19 has shown, it is easier to treat an illness if you understand it. Mental illness is the world’s number one cause of disability, and depression is the largest contributor to this burden. Pre-Covid-19, anti-depressant medications were prescribed to one in eight of the adult population in Australia including one in four older adults and one in thirty children. And yet our rates of mental illness and suicides continue to grow. We clearly need a better approach based on science and proven treatments that get to the root cause of our suffering.

Our hope is that professionally delivered psychedelic therapy using psilocybin mushrooms can meet the massive need for breakthroughs in mental health care.

Action is needed now to ensure that these medicines are accessible and affordable to all and prevent further avoidable suffering and suicides. The recently completed Global Drug Survey showed that thousands of people sought self-treatment for psychiatric conditions and emotional distress with psychedelic-assisted therapies: 85% of them said their conditions improved as a result. People are taking matters into their own hands because they cannot wait any longer for a legal and medically controlled pathway.

Australia was a world-leading innovator in major issues such as the eight-hour work day, women’s vote, our superannuation and healthcare system and so much more. We often initiated positive change, but now our reefs, forests, unique animals, climate and coastlines are under severe threat and our international reputation is losing its shine. We need to find a way back.

Providing safe, medically controlled and legal access to effective medicines to everyone who needs them may be one of the answers. If we want to regain our world leading stature, we all need to reassess what it means to truly be free and make choices about the medicines that may heal us.

The Therapeutic Goods Administration (TGA) is currently conducting an Independent Review to reconsider the rescheduling of MDMA and psilocybin from Schedule 9 (Prohibited Medicine) to Schedule 8 (Controlled Medicine), while the Australian Government also recently announced a $15 million grant round for research into psychedelic-assisted therapies. However, huge obstacles remain, and there is still much to achieve to ensure we catch up and heal the immense suffering.

The next step is to ensure that all Australians enjoy the right to the highest attainable level of health, a right that is recognised under a plethora of human rights treaties Australia has freely ratified. To fully possess this right, everyone needs to have access to all the medicines in the medicine cabinet, and that includes magical mushroom medicine.

Tania de Jong AM

LL.B (Hons), GradDipMus

Scott Leckie

Woman on boat

I am writing this as a mother, in the hope that my words may open the closed minds of our politicians, the TGA and the RANZCP, who we rely upon to ensure every Australian has access to the latest medical therapies.

Our 26-year-old daughter suffers from treatment resistant PTSD and severe depression as a result of a trauma when she was only 11. Rape at any age is devasting, but for a child the impact is profound. We live with the daily fact that with the current treatment of anti- depressants and anti- psychotic drugs available to her in Australia, there is only a 5% chance of her getting well. We also live with the fear that we could lose her. We have journeyed with her for the past 15 years and have seen her suffering as she has tried every treatment available to her. We have all been profoundly impacted by her illness. Our current mental health system has failed our daughter. We need answers. We need treatment. And, we need it now. Tomorrow our daughter may not be here.

Unless you have lived with the fear of your child taking their own life, you will never truly know how it feels. Thousands of mothers, live with that fear every day. Our journey has taken us to countless specialists and across the world. We have watched the work with treatment resistant PTSD using Medicinal MDMA, which is often confused with the recreational drug Ecstasy, Ecstasy is frequently adulterated with more dangerous substances and taken in unsafe environments. We learnt about the outstanding remission rates from Medicinal Psilocybin (which in its natural form comes from certain mushrooms) for treatment of depression. We are confident that these medicines offer real hope. We know that no treatment, even the current ones advocated by our government, is without risks and that the answers are not simple. But we deserve hope.

Clinical trials with medicinal MDMA conducted overseas demonstrate remission rates between 60-80% for treatment resistant PTSD. We were confident Australia would embrace this research in an applied way. Surely, we would act when potentially one of the greatest shifts in psychiatric medicine is knocking on the door? You can imagine our dismay when the TGA refused to reschedule MDMA in its recent Interim Decision. The news was heartbreaking.

The irony is that the TGA is already authorising individual requests from psychiatrists to use these medicines with therapy under its Special Access Scheme, but their listing as prohibited substances in Schedule 9 of the Poisons Standard means that there is no ability to get State and Territory Government approval which is also required so that patients can be treated and have a chance to finally get well. All this will change if they become Schedule 8 Controlled Medicines. What a cruel system we have. Providing hope with one hand and taking it away with the other.

I contacted the TGA for answers and found their response deeply disturbing. Their justifications were not based on data or science, but rather demonstrated deep bias and misrepresentation (for example, calling these medicines ‘illicit substances’ when they would, in fact, be used only in clinical medical environments). Their responses were offensive to sufferers and their families.

I contacted the RANZCP in the hope that they would show the capacity to lead us out of this crisis. It was clear that they cannot accept the facts which are undeniable and globally supported by leading experts, that these treatments are a viable and safe treatment option.

These bodies MUST begin to rely upon the validated data generated by the wider medical community. Do they suggest the outstanding research done at the leading Universities around the world is not valid or sufficient? Do they believe that countries that have enabled psychiatrists to use these therapies under Expanded Access Schemes have done so without high levels of regard? These therapies have been granted Breakthrough Therapy Designation by the USA regulator and my daughter should be given the chance to access these therapies in Australia. Sadly, the Australian community is losing trust in the ability of our institutions to lead us forward. They risk becoming irrelevant as more and more Australians seek treatments conducted illegally by underground therapists.

I contacted every Australian Senator and the common response I have received was “we are sorry for your suffering but it is in the hands of the TGA and RANZCP”. These responses reveal that the TGA and RANZCP have too much power; beyond that of even my elected representatives. I elected my politicians to speak for me and lead us forward, and, as yet, few seem willing to ask if these bodies are advising them correctly and acting in the best interests of Australians. Who will challenge them on my behalf? Has my government forgotten they are here to serve my daughter?

This is so much bigger than my daughter. I speak also for those who don’t have a voice. For the lives already lost and for the families too enmeshed in simply surviving to speak out. Our nation is in a mental health crisis where 1 in 5 Australians have a chronic mental health condition and at least 1 in 8 are on antidepressants including 1 in 4 older adults and 1 in 30 young children.

Anxious adult

Australia should be leading the world in treatment, but instead our system is on its knees, bogged down by regressive thinking that places us as one of the poorest performing countries. We need innovation and leadership from our politicians and our medical establishment. We can make Australia a leader in this field. I imagine a day when the world looks to us. A day when no Australian suffers unnecessarily or dies from a treatable mental health illness.

I have NO doubt that the tide is turning and we will see these medicines rescheduled. The push from Australians like myself, WILL bring about this change. I believe the government knows this too. They know they WILL lose the battle but don’t seem to care about those that will die in the final days of this “war”.

So, it’s time. Enough procrastination, posturing and politics. Our representatives MUST do the job that we have a right to expect of them.

I am praying that the TGA’s announcement this week, that it will be seeking further advice before making the final rescheduling decisions for MDMA and psilocybin will at last mean that the data and facts will come to the surface and block out the bias and stigma. Then finally, change will happen. The TGA has promised an Independent Expert Review into the therapeutic value, risks and benefits to public health outcomes for these medicines. My daughter and so many other sufferers need this so urgently, but I am not holding my breath.

If our government and health agencies continue to fail us, we will be forced to re-mortgage our house and attempt go overseas for treatment. To countries that lead the world in the treatment of mental health. To countries that care in actions, not just words. I will then shout from the roof tops, that my government has failed me and I am deeply ashamed of the country we have become.

Annie Mason

Annie Mason is an educator with a wide range of experiences including classroom teaching K-12, Special Education and Student Wellbeing. She was a Principal for over 15 years and has a special interest in Gender Equity, Social Justice and Women in Leadership. She is a strong advocate for the legal and ethical rights of those with mental health issues.

Person standing near lake

The Royal Commission’s report on the Victorian mental health system sent shockwaves throughout the State, one of which landed squarely on a patient of mine. They noted that Victoria’s mental health system is “not geared for…change”. Just to ensure we got the message, and despite a Federal Government TGA approval, my request to treat my traumatized patient with MDMA-assisted therapy was declined by our state’s regulatory authority.

To be clear, my disappointment lies not with the state government regulators, nor with the medical opinions suggesting MDMA-assisted therapy should not be used for treatment of traumatized patients (despite excellent emerging evidence that it works with little risk). I understand these opinions, though I certainly do not agree with them.

My issue is a more troublesome one. Underlying these opinions is a problem with how we practice psychiatry, which in turn reflects the alienated community in which we live. Mental health paradigms are always a reflection of the society which supports them. You see, us Australians are alienated both intra-personally (from our own emotional worlds) and inter-personally.

Our current paradigms tend to view mental illnesses in a biologically reductive way. In other words, mental illnesses are both understood and treated primarily as biological diseases (which they are not). The posters at your doctor’s rooms will teach you – depression is just like any other medical disease, such as heart-failure or emphysema. In this paradigm, entities such as addictions and depression are seen as distinct phenomena. They are treated in our current system as totally different diagnoses by entirely different teams. The alienated individual who suffers from depression and addiction is labeled with the alienating and erroneous term ‘dual-diagnosis’, which enshrines the division. Furthermore, if addictions are understood (as they are) as inherited conditions (which they are not), and primarily as brain diseases based in dysfunctional dopamine rewards circuits, they will be primarily treated as inherited brain diseases, by doctors with medications.

But what if we have got it all wrong (which we do). You see, addictions are heritable but not inherited (there is a big difference, I recommend looking it up), and the chemical dopamine in no-way explains addictions. Rather, it is the human experience of dopamine (along with numerous other chemicals) which explains addictions, suggesting that addictions are rooted in difficulties with the human experience of life, rather than the neural correlates of those experiences.

The events which lie at the root of illnesses such as addictions and depression are those which overwhelm the mind’s ability to process and integrate. We know that the presence of adverse childhood experiences is present in the majority of (if not all) people with addictions and chronic depression. But rather than seeing these conditions as consequences of trauma (which they are) and treating the underlying emotional issues (which would help), our society mistakes the symptoms (depression and anxiety) for the disease itself. We treat depression as depression and addiction as addiction and all the while we are missing the forest for the trees. The real disease is the high prevalence of trauma, alienation, and neglect in our society. After all, it is these conditions which twist and distort the mind into the contortions which fill the latest catalogues of mental illnesses.

Which brings me back to my patient. Traumatized when young, she has suffered from every diagnosis a psychiatrist’s finger can point at. She has had every treatment a medical guideline can fathom. Yet her trauma remains in place, because no-one has been able to reach it. Suddenly, on the horizon, a change is coming. Treatments like MDMA-assisted therapy appear to touch the root of the trauma, allowing individuals to process the unintegrated parts of their minds, and offer the chance of real healing. But we don’t change. Our outlooks have ossified, our diagnoses have desiccated. And all the while we suffer in our own blindness. People continue to kill themselves, and my patient will continue to suffer in silence until the Victorian Government allows me to access a new treatment which may finally bring peace to a troubled mind.

Dr Eli Kotler

MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA

Eli is a consultant psychiatrist and psychodynamic psychotherapist. He is the Medical Director of Malvern Private Hospital, an addiction and trauma hospital in Melbourne. Eli completed the inaugural CPAT course, and has since been on its faculty. He was appointed as the course’s Australian Course Director in 2023.

As a psychiatric trainee, Eli was awarded the Royal College of Psychiatrists Trainee Prize for his Scholarly Project on Depression, as well as a Research Committee Trainee award for his work on Philosophy of Mind. As an adjunct lecturer at Monash University, he oversees medical students on their addiction medicine rotation, and sneaks in lectures on Philosophy of Mind, Psychodynamic Psychiatry and Psychedelic Assisted Therapies (PAT). He has been invited as a key-note speaker by the RANZCP and International Psychoanalytic Association to lecture on PAT. He has been invited by the Victorian Government to design new addiction programs and works with the AFL players association.

Eli is an Associate Fellow of the Royal Australasian College of Medical Administrators, and is a member of the Australasian Professional Society on Alcohol and other Drugs. He also has extensive research experience with novel therapeutics for neurodegenerative diseases. He sits on the Victorian Medical Panels, and is an expert witness in historical abuse cases.

Clinically, Eli works in a psychodynamic framework, and attempts to help his patients find freedom from their addictions and trauma through relational experiences, and experiential self-awareness. He is actively treating patients in Australia with MDMA-assisted therapy.

Unraveling the inspiration behind various acclaimed Disney films.

Can psychedelics be used to address childhood trauma and better understand imagination?

Walt Disney films are a cornerstone of childhood. Today, the Disney corporation is one of the most powerful media and entertainment enterprises in the world. Without even realising it, the company has probably influenced your own imagination, and in some way shaped your beliefs, values, and morals. However, before it turned into a global giant, it all began with a mouse.

Undeniably, Walt Disney had an enormous influence on the animation industry. He is the most renowned animator, filmmaker, screenwriter, and producer in cinematographic history. Hailed as “the Father of Animation”, he was the first to pioneer full length cartoons with synchronised sound and technicolour. Walt had one of the most important impacts on the development of animation and ultimately produced over 650 films or shorts in a career that spanned decades. Since then, Disney researchers and animators have continued his legacy, with further contributions to animation, science, and technology.

While Walt Disney’s career is not without pitfalls and controversy, it is indisputable that he changed the world with his creativity. How did he manage to always keep that childlike perspective? As Walt himself said, “That’s the real trouble with the world, too many people grow up.”

Disney was known for being an innovator. He was continually one step ahead of his peers and was constantly seeking new ideas. Could it be that the act of his creative mind was influenced by psychedelics? Walt is not alive to confirm or deny these rumours, yet widespread speculation of his use of hallucinogens is commonly assumed. Perhaps we will never be able to prove these claims, but there is one thing that is certain — the magic of Mr. Disney was his ability to preserve his childlike imagination throughout his lifetime.

There has long been reports that members of the creative Disney team were involved in the use of psychoactive substances. Is it such a far cry for Walt himself to have indulged as well? According to a letter by Paul Laffoley, an American visionary artist, Disney was indeed influenced by the hallucinogen mescaline, found in the Peyote cactus (Lophophora williamsii).

The letter goes on to say that in an attempt to explain “artistic implications of the new field of animation”, Walt arranged an interview with Josef Albers, the artistic director for the experimental liberal arts school — Black Mountain College in North Carolina. Josef, however, turned down the request. As a result, Walt then switched his intentions to the students at the college to aid his animated ventures. It was during this interaction with the students that he learned of their avid use of mescaline during their summer breaks in Northern Mexico. Laffoley claims this was the catalyst needed for Disney to become a frequent user himself.

Mescaline is a psychedelic alkaloid that occurs naturally in Peyote, San Pedro, Peruvian Torch, and other cactus varieties. These plants produce an experience similar to LSD or magic mushrooms: extravagant visuals, increased sense of connection, appreciation toward small and mundane details, and novel interpretations of the world around you. Studies show that mescaline can enhance creativity, which would explain why the art students would be enthusiasts of the substance.

Walt genuinely was determined to make real art. He was not only inspired by the natural world, but also by other visionary artists. This motivated him to team up with famed surrealist artist Salvador Dalí for the movie ‘Destino’, which initially started in 1945 but only saw eventual completion in 2003 by Walt’s nephew Roy E. Disney. Although the project was put on the back burner, both artists got more than what they bargained for out of their partnership. What started as a creative collaboration led to a lifelong friendship. Salvador Dalí is well known to have incorporated the psychedelic experience in many of his creations. With infamous artwork such as ‘The Psychedelic Flower’ and ‘The Hallucinogenic Toreador’, it would seem Dali was very open about referencing psychedelic terminology.

Another good friend of Walt Disney was none other than well-known and prolific English writer Aldous Huxley. Best recognised for his novel ‘Brave New World’ which presents a world where psychological manipulation is encouraged by regularly taking the drug ‘Soma’ — a potent hallucinogen that creates a strong sense of well-being. Additionally, Huxley is known for the notorious psychedelic inspired ‘Doors of Perception’ where he openly recounts his experience with the psychoactive compound mescaline.

In the fall of 1945, Disney brought in Huxley to work on the live action animation script for what was to become ‘Alice and the Mysterious Mr. Carroll.’ It has been stated that Walt rejected the script because it was too “literary” and didn’t capture what he wanted. Sadly, a fire destroyed more than four thousand of Huxley’s annotated books and documents, including most of his involvement on the ‘Alice’ project. Fortunately, the Disney Archives still has some of the story meeting notes and parts of the original script.

The classic children’s book ‘Alice’s Adventures in Wonderland’ by Lewis Carroll, is a tale that revolves around a girl who quite literally falls down a rabbit hole and finds an entirely new world to explore. Examining the psychedelic undertones within Alice in Wonderland’s storyline is not a recent phenomenon. The theory has been pursued by artists and critics alike. There is a possibility that people attribute this because it was written during an era when psychedelic use was rampant, not necessarily because Carroll was actually under the influence of anything. However, with characters like the hookah smoking caterpillar and the fact that Alice finds herself under the influence of a mushroom does make you wonder if the story was a by-product of mind-altering drugs.

No one knows for sure if Walt Disney himself was truly an avid user of hallucinogens. None the less, there is no doubt that he had many connections with certain collaborators who were well-documented in partaking in altered states of consciousness. Additionally, Disney’s work frequently reflected that of the psychedelic experience itself.

These references in Disney films are not an unusual occurrence. The feature film ‘Fantasia’ was even re-released in 1969 with a psychedelic poster and embraced by the counterculture amid speculation that Walt was under the influence when he produced it. The popular hallucinogen at that time was LSD, which wasn’t brought to the USA until 1949, too late to have been the original driving force behind Disney’s Fantasia. It is more likely that mescaline was involved.

The combination of classical music and visuals of nature coming to life is a typical blueprint of the entire psychedelic experience. Even the casual observer would notice the impressive context and landscapes in Fantasia. In particular, scenes such as the dancing Amanita Muscaria toadstool mushroom fuels the psychedelic influence speculation. The species contains two main psychoactive compounds, ibotenic acid and muscimol.

This scene was created by animator Art Babbitt, who was fully aware of the gossip surrounding the film and its possible link to drugs. So much so that in an interview, he sarcastically quipped: “Yes, it is true. I myself was addicted to Ex-lax and Feenamint” — which are merely over the counter laxatives. Other psychedelic plants can similarly be spotted in the film. These include: Morning Glory (LSA), Angel Trumpets (Scopolamine), Poppies (Opium), and what appears to be Datura (Atropine).

Fantasia is still considered one of the best visual works of all time. It continues to astound even though it was made in 1940. It’s mythological, spiritual, and occult visuals mixed with massive musical scores paved the way for animation. It allowed other animators to think outside the box. Walt even invented the multiplane camera to give the film the depth and dimensions to immerse the viewers visual senses. Disney was aware that the feature was an intricate and complex piece of art, that was unlikely to grab the attention of young children. What he wanted was to create discussion among the adults by presenting a work that changed the way they thought.

Fantasia is not the only Disney film that includes psychedelic undertones. Another infamous substance inspired clip was in the 1941 film Dumbo. The Pink Elephants on Parade is one of the most iconic trippiest scenes in cinematic history. Naturally at the time, it was negatively received and a risky move for a company who was in financial distress. The song is the result of a drunken trip Dumbo and Timothy have after inadvertently drinking a bottle of champagne. The pair start to hallucinate a collection of Pink Elephants. The lyrics of the song do a decent job of summing up the intensity of a psychedelic trip — “Technicolor pachyderms is really too much for me.” The scene is unlike anything Disney had ever done or has ever done since.

Countless other scenes in Disney animations such as Pinocchio, Peter Pan, 101 Dalmatians and The Little Mermaid show characters smoking. As a result, these movies have now had their availability limited on streaming services. Obviously, not all these scenes are referring to psychedelic use, however, some do seem questionable. In particular, the clip of Pinocchio’s reaction after inhaling what appears to be an ordinary tobacco cigar. His head spin seems fairly intense after his ne’er-do-well friend Lampwick tells him he is not doing it right. “Take a big drag. Like this.” The effect suggests many Disney animators might have been familiar with a bong.

You may be asking yourself; okay Disney was possibly inspired by psychedelics? So what? Well, since psychoactive compounds are still illegal in most countries, I believe it is critical to expose and emphasise the numerous key public figures that used these medicines. Not only have they certainly been the motivation for art and music, but behind notable innovations that have impacted the world, and changed the course of history. We may owe a lot more to psychedelics than we think.

They additionally have the potential to change the current mental health paradigm. Statistically this is getting worse every year, especially in children, and exaggerated by the current Covid-19 pandemic.

Sure, back in Walt Disney’s time the state of the world was certainly not all positive. Post World War II would have had an enormous traumatic effect on the collective consciousness. However, in general people’s lives would have been much more sheltered, contained and community based.

Humans today are exposed to more information than ever before. Scientists concluded that in 2011, Americans took in five times as much information every day as they did in 1986. This overwhelms the brain and continues to cost our mental faculties a great deal. The rise of social media in combination with consumerism, has led to an unrealistic view of our ourselves and what we think we should be. Constant exposure to the world’s troubles, have a detrimental effect on our psyche and raises levels of depression, anxiety, and addiction.

Walt was always focused and dedicated to family entertainment. He was determined to create Disneyland even when it was shunned by the rest of the Disney team. It was a major financial risk to the company, and Walt had to borrow from his life insurance to help fund the project. Fortunately, his vision paid off and today Disneyland is considered the most successful amusement park of all time. Walt truly wanted a place for children and adults to come together. Encouraging grown-ups to connect to their imagination without fear of judgement.

Interestingly, psychedelics seem to aid in connecting fully developed adult brains to their childhood state of mind. Carhart-Harris, a popular psychedelic researcher and Alison Gopnik, a researcher of Psychology at UC Berkeley, have both stated that the effects of psychedelics seem to resemble the mind of an infant.

Research using fMRI scans show that children have decreased default mode network (DMN) activity compared to adults, something that is observed in psychedelic users as well. The DMN is thought to be involved with ‘resting state consciousness’ and tasks requiring one’s attention seem to suppress this network. The DMN is not as strong in children because they have yet to develop strategies of ‘auto-pilot’ work, requiring more immediate awareness than adults. It also has to do with a less conditioned state of mind, as the DMN can be known as our ‘inner critic’.

Dr. Robin Carhart-Harris explains how the effects of psychedelics can assist those struggling with psychopathologies, that can be caused by certain childhood traumas and experiences. “Certain patterns, certain configurations in the brain can become overly reinforced. And some of the range of brain activity becomes sort of narrowed and limited. If you have these very debilitating disorders, then perhaps you could introduce something like LSD, which works to introduce a kind of window of plasticity or malleability — conditions for change, essentially — to try and sort of dismantle these entrenched patterns.”

It goes without saying that these medicines should only be used by adults. Legalising psychedelic psychotherapy could greatly assist those struggling, therefore, having an immediate effect on the way we raise the children of tomorrow. If done so with careful preparation, attendant psychotherapy, and proper integration psychedelics perhaps have the power to create a better future for all.

Disney Pixar’s newly released ‘Soul’, is an incredible exploration of the meaning of life. It is not the first time a Disney movie has posed the kind of big-life questions that face many middle-aged adults. The film is known in the Disney community as a sort of next chapter of the animation ‘Inside Out’ (which depicts characters that represent certain emotions, in the hopes of explaining psychological concepts to children). Both were equally successful at the box office and in exploring the metaphysical.

Soul’s protagonist, Joe, goes on a spirited adventure and is faced with questioning his purpose, if his dream was enough to fulfill him, and what life is really about. After finally getting his big break, Joe accidently dies and is drawn towards the proverbial light (similar to descriptions of 5meo-DMT and near-death experiences). Ultimately, spoiler alert, one of the movie’s many morals is that it is the little things that truly make life worth living. Joe realises that happiness may not arrive from accomplishing that which he dreamed of, but rather, by appreciating each quotidian moment.

In the film, “lost souls” wander the astral plane because they are anxious and depressed. Becoming too obsessed with anything, even if you believe it is your purpose, can lead to dissatisfaction and a disconnection from reality. Moonwind, the captain of a psychedelic galleon bearing a troupe of “mystics without borders”, helps rescue the lost souls. These characters also mention other transcendental practices or techniques such as yoga, meditation, drumming and psychotherapy.

The movie wants to leave its audiences asking questions about the meaning of life and the human experience as a whole. Introducing complex themes to children such as the idea of the flow state in the creative process, the fleeting nature of life itself and other philosophical debates. The fact that Disney animation is so comfortable with talking about the meaning of existence is a testament to how far we have come.

Personally, it is similar to my own experience with taking psychedelics, which in fact was the inspiration behind this article. I suppose the teachings and insights I received were similar to those themes explored through various Disney movies, even once seeing the Cheshire Cat during an Ayahuasca session in Peru. While there is already wisdom behind this character, the cat strangely explained to me through various visions that life is a riddle, and I will never figure it all out. Further reminding me that life is absurd and laughing at that is part of life’s whole trip.

I have directly struggled with mental health issues, especially with my own self-image. I believe this is associated with my childhood experiences; however, it has been further exaggerated by societies focus on the external. Psychedelics helped me better embrace my quirks, talents, and gifts that I have to give to the world. It was the first time I truly saw myself for who I am — a spiritual being having a human experience. It gave me a deeper understanding of the reasons why we are here.

Disney has always provided its audience with profound meanings. Some films are majorly influenced from ancient cultures and native indigenous spirituality, some who are well-documented for using plant medicines as a healing tool. These messages can be heard in the soundtracks from films such as Pocahontas, Brother Bear, The Lion King, Tarzan, Moana, Mulan, and the Hunchback of Notre Dame. Disney has forever been teaching children about understanding those with different backgrounds. With lyrics like “Show us that in your eyes, we are all the same” from Brother bear or “You think you own whatever land you land on; the Earth is just a dead thing that you claim” from the renowned ‘Colours of the Wind’. And who could forget the deep-rooted ideas in the iconic ‘Circle of Life’ from The Lion King, showing us the connectivity of everything.

In a world that is trying to make us fit in, Disney inspires us to stand out. What makes us different, makes us unique. As we grow older, we are no longer encouraged to be creative or playful. Becoming an adult is inevitable and can be wonderful when we hold onto our childlike curiosity. Certainly, nobody wants to be that person with Peter Pan syndrome. Yet, it is healthy to be reminded that we once were all children, trying to figure out and navigate the world around us. We still have an inner child; we must learn how to connect and heal them. A great deal of work is done in therapy around parenting your own inner child.

The reason Disney films are notorious for striking a chord with our emotions, is because it reminds us of our own childhood. We become nostalgic of a more innocent time when we would let our imaginations run wild. Sentimental of a period when the little things in life bought us so much joy. This is a key ingredient to healing the trauma of our collective past. Psychedelics reminds us of the magnificence of creation. They push us to take better notice of the beauty in nature or the emotion behind music. They help us see the interconnectedness of everything.

So, perhaps next time you sit down to watch a treasured Disney film or go to play one of their unforgettable classic movie soundtracks; you will have greater appreciation for those magical plants that maybe inspired fantasy worlds to be bought to life. I believe that they influenced and even played a starring role in countless Disney masterpieces. Seems in many ways, psychedelics and Disney go hand in hand, always encouraging us to bring more animation into our lives.

REFERENCES

Fast Company. 2021. Why It’s So Hard to Pay Attention, Explained by Science. [online] <https://www.fastcompany.com/3051417/why-its-so-hard-to-pay-attention-explained-by-science> [Accessed 6 March 2021].

Flicks.com.au. 2021. The meaning of Fantasia, Disney’s beloved psychedelic masterpiece. [online] <https://www.flicks.com.au/features/the-meaning-of-fantasia-disneys-beloved-psychedelic-masterpiece/> [Accessed 2 February 2021].

Maltin, L., 2021. When Disney got trippy. [online] Bbc.com. <https://www.bbc.com/culture/article/20151112-when-disney-got-adult-and-trippy> [Accessed 2 February 2021].

Medium. 2021. LSD, Childhood Memories, And the Science of Nostalgia. [online] <https://medium.com/@psychedelicsaremedicine/lsd-childhood-memories-and-the-science-of-nostalgia-32bebb1fe1e9> [Accessed 6 March 2021].

Npr.org. 2021. NPR Cookie Consent and Choices. [online] <https://www.npr.org/2016/04/17/474569125/your-brain-on-lsd-looks-a-lot-like-a-babys> [Accessed 6 March 2021].

Open Culture. 2021. When Aldous Huxley Wrote a Script for Disney’s Alice in Wonderland. [online] <https://www.openculture.com/2014/12/when-aldous-huxley-wrote-a-script-for-disneys-alice-in-wonderland.html> [Accessed 15 February 2021].

Paullaffoley.net. 2021. » Walt Disney and Josef Albers Official Paul Laffoley Website. [online] <https://paullaffoley.net/writings-2/walt-disney-and-josef-albers/> [Accessed 21 February 2021].

Psychology Today. 2021. “Soul:” A Psychedelic Adventure into Meaning. [online] <https://www.psychologytoday.com/us/blog/psyche-meets-soul/202101/soul-psychedelic-adventure-meaning> [Accessed 25 February 2021].

Gwerky science. 2021. The Phoenix Effect: Reversing Mental Age with Psychedelics. [online] <https://mad.science.blog/2020/08/16/the-phoenix-effect-reversing-mental-age-with-psychedelics/> [Accessed 6 March 2021].

Secret of the Vine. 2021. Disney Psychedelics & the Occult | Secret of the Vine. [online] <https://www.secretofthevine.com/disney-psychedelics-and-the-occult> [Accessed 28 January 2021].

Psychedelic Prism

I want to start with a snapshot of how I am possibly different from the average person. I don’t smoke or drink. Before this chapter of my life began, I’d never taken any drugs besides prescription medication (and those as rarely as possible). I live in Melbourne, the coffee capital of Australia, and don’t even drink it.

Yet today, my life revolves around psychedelic medicines – heavily stigmatised substances still illegal in most countries. This huge shift is likely confusing. However, my personal journey can hopefully provide a deeper understanding of why I co-founded Mind Medicine Australia (MMA), and how psychedelic-assisted therapies could change the face of mental health treatment.

Helping People find their Voice

Over the past two decades, I’ve founded 6 companies, 3 charities and am a Member of the Order of Australia. I’m a global speaker and an international soprano – performing both as a soloist and as part of a group and have released 12 albums.

Singing has always been a huge part of my life. This motivated me to create the charity Creativity Australia and social inclusion program, With One Voice. My mission was to bring together people from different backgrounds, generations, faiths, and cultures by forming social inclusion choirs that bring together ‘haves’ with ‘have-nots’. Singing together can help alleviate loneliness, depression, and social isolation. I explain this further in my recent TED talk, which has received over 100,000 views so far.

I’ve personally witnessed that helping people find their voice can unlock their full creative potential. Similarly, I also believe psychedelics have a monumental role in helping achieve this. I know they will allow me to scale this mission… but I’ll get back to that. First, I think it’s important to tell you about my own experiences with psychedelics.

From Sober to Psilocybin Seeker

Taking an illegal substance had never occurred to me until I stumbled across Michael Pollan’s article in The New Yorker titled ‘The Trip Treatment.’ Reading it not only made me aware of the current resurgence in psychedelic research but also helped me to understand how these ancient plant medicines were assisting people to heal from a host of mental health issues.

From that point on, my interest in trying these hallucinogenic plants began to grow. I had no idea what it was like to be drunk or out of control. Yet the majority of people expose themselves to these altered states on a regular basis. I wondered if perhaps I was missing out on an essential human experience. What could psychedelics teach me about who I am or who I could be? Through exploring my psyche, what unknown parts of myself and our cosmos could psychedelics grant me access to?

So, I recruited the support of my now-husband Peter, and set out on a quest to have a therapeutic experience with psilocybin mushrooms. Having sadly lost his father to suicide in his early teens, Peter was also interested in dealing with past traumas.

However, being able to do this in a safe and legal setting proved difficult. After first trying and failing to get into global trials for healthy patients, we were ultimately referred to a private therapist in the Netherlands, where the use of psychoactive truffles is legal. We ingested a large dose of psilohuasca – a combination of psilocin-containing fungi and Syrian Rue, a MAO inhibitor used to enhance and prolong the effects of a trip.

The Inner Journey

Fair warning – describing what it’s like when you take psychedelic substances is difficult. My first time was completely removed from anything I’d encountered before. Unless you’ve personally experienced it, there’s really no reference point for understanding what it’s like. However, I can tell you that from then on, my life veered off in a very different direction.

The combination of having never lost control before and hearing stereotypes around psychedelics, made me incredibly nervous. I believed that it was going to destroy my brain. Turns out, this is far from reality. What happened was one of the most meaningful experiences of both our lives.

Firstly, the medicine completely shot us into space and, at the same time, through the Earth, rivers and oceans. What initially overwhelmed me was this incredible sense of oneness.It was as if all boundaries dissolved and I was left with the sheer magnificence of our planet. The connectivity of everything was indescribable. I haven’t been able to eat meat or even step on an ant since.

Being confronted with personal pain is a common experience during a psychedelic trip. For myself, as the daughter and granddaughter of Holocaust survivors, I’ve lived with transgenerational trauma my whole life. I was faced with this horror during my experience and have undergone transformational healing as a result.

These realisations were profound, but it’s the deeper insights we gained about ourselves that have left a lasting impression. The self-development Peter and I dove into following that first overseas expedition was vital for us to really integrate our life-changing experience. These lessons were so powerful, we didn’t feel compelled to have another session for a whole year. Research shows that the psychedelic experience significantly decreases activity in the brain’s default mode network. However, it’s the work that’s achieved in subsequent integration that leads to lasting wisdom. Incorporating the experience into your life, is just as important as the experience itself.

The neurogenesis and increased neural plasticity created by the medicines is truly remarkable. It’s like hitting the reboot button on your brain’s computer and defragging the faulty drives. I’ve noticed my creativity has increased tremendously. I’m able to access more moments of flow and purity in my singing, public speaking and writing. I’ve also recognised real lifts in my energy and consciousness. I feel many neural pathways have reconnected for me, new ones have formed and missing parts of myself have been found.

Psilocybin and Placebo

Creating a Movement and Making a Difference

Fast forward a few years later and Peter and I now seek out a session every four to six months. We call it our reset button. Every time we work with these medicines, we get new downloads and join more dots. Not only have we woven psychedelics into our lives, but the immense value we’ve gained from these magical medicines is what inspired us to establish our fifth charity, Mind Medicine Australia in 2019. Whilst our other charities are helping thousands of people through women’s shelters, social inclusion choirs, educational programs, poverty alleviation and microfinance, we acknowledge that at the heart of any kind of social isolation or disadvantage lies mental illness.

Mental illness keeps a person isolated. Sufferers often deal with rigid, negative thought patterns and intense feelings of despair. Every day we get emails and calls from those who’ve tried medication or therapy and are at the end of the road. We need to treat the underlying cause if people are to genuinely heal and lead more meaningful lives.

Having celebrated our second anniversary in February 2021, MMA is focused on expanding the treatment paradigm available to specialist health practitioners to reduce Australia’s terrible mental health statistics, which are worsening because of the current and ongoing COVID-19 pandemic. Of particular concern and pertinence are the high levels of mental illness, addiction, and suicide amongst the veteran, first responder and other marginalised population groups.

Before the pandemic, 1 in 5 Australians were experiencing some type of mental illness. 1 in 8 adults, 1 in 4 older people and 1 in 30 children (some as young as four) were estimated to be on anti-depressants. Their use across the country has risen by a massive 95% over the past 15 years. Still, mental health statistics continue to get worse, resulting in one of the highest rates of mental illness in the world. Recently, mental health experts announced that the COVID-19 crisis could lead to a 25% increase in suicide rates. Incidence of trauma, anxiety, depression and substance abuse are all accelerated by the pandemic.

Depression treatment methods haven’t substantially changed for decades and reversion rates are as high as 80% following medication. Side effects and withdrawal symptoms are common problems. Anti-depressants and psychotherapy lead to remission for less than 35% of suffers and the rates for PTSD are around 5%.

On the other hand, MDMA and psilocybin-assisted therapies are considered safe with remission rates of between 60-80% being achieved from over 150 current and recent trials. Evidence suggests psychedelics are low in toxicity, non-addictive, and show no signs of producing organ damage or neuropsychological side effects. These medicines are also proving to be very effective at treating various addictions. Practitioners describe them as ‘antibiotics for the mind’ due to their outstanding efficiency and short nature of treatment programs.

Research showing the benefits of these therapies are taking place at many of the world’s most prestigious universities including Johns Hopkins, Yale, UCLA, Harvard, Oxford and Imperial College London. Furthermore, these therapies are already legally available in the USA, Switzerland, Canada, Israel via Special Access Schemes. Some psychiatrists and prescribing physicians we work with have also recently received approvals for use of MDMA and psilocybin-assisted therapy for their treatment resistant patients via Australia’s SAS-B pathway.

Psilocybin-assisted therapy for depression and MDMA-assisted therapy for PTSD have achieve “Breakthrough Therapy” designation from the FDA in the USA. This designation is only granted to medicines that could be vastly superior to existing treatments to fast-track the approval process. MDMA, which is in Phase 3 trials, is likely to be a prescribed treatment for PTSD in the USA within 18 months. There are also trials underway for the treatment of end-of-life depression and anxiety, alcohol and drug addiction, dementia, strokes, anorexia and other eating disorders, cluster headaches and chronic pain.

Scaling the Mission to Set People Free

In preparation, we need to ensure that practitioners are properly trained. Our Certificate in Psychedelic-Assisted Therapies commenced in January 2021. This is the first course of its kind in this field in the Southern Hemisphere and is being designed in collaboration with the world’s leading programs and features a Faculty of global leaders in this field. Both our intakes for 2021 are proving popular with practitioners including psychiatrists, psychologists, GPs, mental health nurses and social workers.

Mind Medicine Australia is in the process of establishing an Asia-Pacific Centre for Emerging Mental Health Therapies. Its main mission is to expand the mental illness treatment paradigm in Australia and boldly position Australia as a global leader in mental health innovation, with partnerships encompassing University, philanthropic, private industry, and government sectors. MMA is also a part-funder of the nation’s first psychedelic clinical trial, currently underway at Melbourne’s St Vincent’s Hospital. We are also currently planning a Major International Summit for 2021, attracted a great Board, Advisory Panel and have support from major players in the psychedelic space. These include pioneers Roland Griffiths from Johns Hopkins University, David Nutt and Robin Carhart-Harris from Imperial College London, Rick Doblin from MAPS and many others.

What psychedelic medicines provide is an extremely effective treatment option for medical professionals who are desperately seeking innovation in the way we treat mental illness. They can help us rediscover our connection to ourselves. We can’t love others unless we first love ourselves. Psychedelics used intentionally also have the potential to help us solve other serious challenges, such as environmental and political issues, homelessness, and domestic violence.

A great deal of pain and suffering could be alleviated by introducing genuine connection back into people’s lives. If the pandemic is teaching us anything, it’s that humans are social creatures, and losing that connection can drastically affect our health and wellbeing. My first mission was to heal through the power of music, and don’t get me wrong, I’m still very dedicated to doing this. Yet today, with MMA, we’re taking that mission and scaling it in a way I could’ve never imagined possible.

Tania de Jong AM

LL.B (Hons), GradDipMus

Psychotherapy assisted by psilocybin, a naturally occurring compound in ‘magic mushrooms’, has recently received ‘Breakthrough Therapy’ status from the FDA, in recognition of the substantial benefits witnessed in clinical trials investigating treatment-resistant depression. A number of trials of psilocybin-assisted therapy are also underway for major depressive disorder, one of the most significant causes of disability worldwide (1), and the modality has the potential to support the long-term cessation of tobacco- addiction to which kills some 5,000,000 people per year – more effectively than any other available treatment (2). As such, it seems certain that therapy assisted by psilocybin and other psychedelics will receive significant interest from the biotechnology sector, psychiatry research and public health policy over the coming years.

However, for all its apparent promise, psychedelic-assisted psychotherapy remains extremely under-researched from a bioethical perspective. This is a serious shortcoming, and with licensing around the corner, it is now also an urgent problem. Against the backdrop of regular healthcare, the experience of psychedelic-assisted psychotherapy, its mechanisms of action, and its downstream consequences, are all pretty unusual. So perhaps unsurprisingly, pre-existing bioethical accounts of mental health treatments are challenged by this new treatment along a number of directions.

A full account of potential ethical challenges embedded in psychedelic-assisted psychotherapy, and a clear articulation of the clinical and policy choices that can defuse these challenges, will be a vital component in establishing psychedelic-assisted psychotherapy within the mainstream of healthcare. The clinical promise of psychedelics is only part of the story – the success of a technology or treatment depends not just on its efficacy, but also on a slew of social facets of the culture it is embedded in. Not only do we want to have our ethical house in order before there is widespread uptake of psychedelic psychotherapy, but getting the ethics right will also facilitate widespread uptake.

Suppose we forge ahead without deep, critical ethical engagement, and we overlook something that we could have fixed, that leaves patients feeling let down, violated, or otherwise not properly considered. Not only would that amount to a failure of a physician’s duty of care, it would cost the psychedelic psychotherapy movement itself: maybe the loss of the public goodwill that has been so hard to build, maybe a series of litigation actions that make treatment providers, insurers, and decision-makers in other jurisdictions considerably less enthusiastic about facilitating psychedelic psychotherapy, ultimately meaning that many other people who could benefit would miss out. By seeking out potential problems now, and thinking about how to manage or accommodate them, we thereby minimise these risks.

A useful prism through which to understand some of these bioethical challenges is the tranche of unusual, non-clinical ‘side-effects’ of psychedelic experiences. Alongside the target clinical effect, psychedelic experiences can increase prosocial disposition, affect attitudes towards death, enhance aesthetic appreciation and improve patients’ sense of personal well-being and life satisfaction (3,4,5,6). Perhaps most interestingly, they can induce mystical experiences of long-lasting spiritual significance (7), and produce robust changes to religious belief (8) and personality (9,10). Such experiences appear to be a feature, rather than a bug, of psychedelic psychotherapy, with the intensity of the mystical experience correlating with the extent of clinical benefit. Of potentially wider significance, they might cause long-term changes to political values and, perhaps, behaviours (3, 11).

The focus on the therapeutic potential of psilocybin-assisted therapy has meant that the significance of these non-clinical outcomes has been underestimated. But their importance could hardly be overstated: even where psilocybin-assisted psychotherapy proves an effective treatment, participants can report this clinical success as one of the least important effects of the experience, when compared to the other changes (6). Given the unique power that this treatment has to influence facets of a patient’s character that cut to the very core of their identity, it is imperative that the breadth of its potential impact is carefully and critically examined. With the knowledge of these changes, clinicians who conduct psychedelic-assisted psychotherapy are knowingly changing people in a fundamental sense, far beyond the bounds that are usually seen within medicine.

The reflexive response to such ‘side-effects’ from some strains of medical ethics would be to square them away by appeal to the dominance of autonomously given, informed consent: so long as a patient is adequately briefed of the possible consequences of a treatment, their decision to continue with a treatment is conclusive. But the intuitive understanding of informed consent faces a number of challenges with psychedelic-assisted psychotherapy. The superficial challenge is that the very nature of the mystical experience induced by psychedelics runs contrary to the mainstream understanding of informed consent. A core characteristic of mystical experiences is that they are ineffable – inexpressible or incomprehensible in linguistic terms. Insofar as patient briefing takes place linguistically, securing informed consent will not be straightforward.The deeper problem with understanding informed consent in the context of psychedelic medicines, is to find a secure standpoint from which to make judgments of autonomy. Commonplace advice to people considering whether to undertake a medical intervention, is to choose whichever option leads to a better quality of life, all things considered. But judgments about quality of life are necessarily dependent on a system of values, and values themselves can be changed by psychedelic-assisted psychotherapy. If you know your perspective on life may radically change following psilocybin, how do you adjudicate between your current evaluation of prospective quality of life after psilocybin, and your likely post-psilocybin evaluation of quality of life after treatment? (12) This is not a mere philosophical puzzle. How might we counsel a prospective patient considering psilocybin-assisted therapy who has debilitating depression and is a fervently proud, card-carrying materialist atheist. From this patient’s perspective, coming out of treatment believing in God or some sense of Ultimate Reality may be more horrendous to consider than continued clinical suffering. But, were this patient to proceed with treatment and have a religion-inducing ‘God-encounter experience’ (8), they would not have nearly as negative an evaluation of this newfound belief, after the fact.

With the non-clinical changes following psilocybin administration come questions of authenticity, self-conception, and self-development. Psychedelics are far from the first treatment to challenge these notions in psychiatry. The expansion of SSRI prescription in the 1990s led to worries about ‘cosmetic psychopharmacology’ and patients ‘losing themselves’ to Prozac (13,14) . The personality characteristics and outlooks that develop in users of SSRIs do not truly belong to them, it is argued, given their lack of connection to the patient’s overall narrative arc and environment (14). Prima facie, some drivers of change seem more authentic than others. Changes that come about from slower-acting, experiential factors (a period of missionary work, the raising of a child) seem intuitively more plausibly ‘authentic’ than those that come about by faster acting, exogenous, artificial factors clearly linked to neurological disruption (a railroad spike through the left frontal lobe, a six week course of SSRIs). But psychedelic-assisted psychotherapy refuses categorisation under this schema. Although the changes are detectable rapidly, and come about following the administration of a drug with a dramatic acute and post-acute effect on brain function (15,16), psychedelic experiences are, nonetheless, experiences. Indeed, they are experiences that tend to be ranked among the most meaningful in a patient’s life (3), making them more credible candidates for authentically cohering with, or indeed shaping, the narrative arc of a patient’s life. Further exploration and elaboration of these ideas, as well as being philosophically interesting, can usefully feed into public narratives about the meaning and significance of clinically administered psychedelic experiences: it is a strange medical treatment indeed that returns patients to their loved ones not only freed from their tobacco addiction, but also with a perceptibly different personality, a penchant for spending time in nature and art galleries, and a newfound spirituality (2, 6). A clear articulation of the authenticity of these changes, if they can be understood as a natural and comprehensible expression of continuity, rather than an exogenously-imposed transfiguration, could serve to assuage suspicion or mistrust of psychedelic medicine among patients’ loved ones, and the wider public.

These are just a few of the surprising ethical quandaries that lurk within psychedelic medicine. While some of the challenges may seem theoretical or philosophical, the sharp end of each of them is to be found in the clinic, requiring sincere and critical reflection on the part of the psychedelic research community, and perhaps ultimately incorporated into the soon-to-be-expanding training programmes for therapists.

By Eddie Jacobs

References

1. https://www.who.int/news-room/fact-sheets/detail/depression

2. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse, 43(1), 55-60.

3. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., …& Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197.

4. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … & Su, Z. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology, 30(12), 1165-1180.

5. Garcia-Romeu, A., R Griffiths, R., & W Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews, 7(3), 157-164.

6. Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. Journal of Psychopharmacology, 32(7), 756-769.

7. Doblin, R. (1991). Pahnke’s “Good Friday experiment”: A long-term follow-up and methodological critique. Journal of Transpersonal Psychology, 23(1), 1-28.

8. Griffiths, R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019). Survey of subjective” God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PloS one, 14(4), e0214377.

9. MacLean, K., Johnson, M., & Griffiths, R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453-1461.

10. Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R.L. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica,138(5), 368-378.

11. Lyons, T., & Carhart-Harris, R. L. (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 32(7), 811-819.

12. Schick, F. (1997). Making choices: A recasting of decision theory. Cambridge University Press.

13. Kramer, P. D., & Kramer, P. D. (1994). Listening to prozac. London: Fourth Estate.

14. Elliott, C. (1998). The tyranny of happiness: Ethics and cosmetic psychopharmacology. Enhancing human traits: Ethical and social implications, 177-188.

15. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … & Hobden, P. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143.

16. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., … & Leech, R. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports, 7(1), 13187.

About

Training

Research

Access

Learn

Events

News

Support us

Contact

Mind Medicine Australia’s First Five Years: Progress and Achievements

Awareness and Knowledge Building

Patient Access

Professional Development Program

Research

Noteworthy from Media Releases:

Tania de Jong AM

Peter Hunt AM

Returning to Our Roots

REFERENCES

Charlotte McAdam

Psychedelic Healing Stories from Australia: John’s Experience with MDMA, Psilocybin and Ayahuasca

Psychedelic Healing Stories from Australia: Maree’s Story with Psilocybin and LSD

Psychedelic Healing Stories from Australia: Charlotte’s Experience with Psilocybin

A message from Dr Simon Longstaff AO

Dr Simon Longstaff AO

If the Medicine Works Shouldn’t We All Have Access to it? A Recent Poll of Australians Says Yes We Should By Scott Leckie and Tania de Jong AM

Scott Leckie

Tania de Jong AM

Psychedelic Healing Stories from Australia: Daniel’s Experience with DMT and Psilocybin

What led you to seek healing through psychedelic medicine?

What was your psychedelic experience like?

How have you been able to integrate this experience? How has it contributed to your healing process?

Will Australia take a lead in psychedelic therapy? By Kevin Ke

What’s the evidence for psychedelic-assisted therapies?

How does psychedelic assisted therapy work?

An independent expert review

Anyone for a Magic Mushroom Medicine? By Tania de Jong AM and Scott Leckie

Tania de Jong AM

Scott Leckie

A Mother’s Prayer To The TGA by Annie Mason

Annie Mason

Healing A Troubled Mind: A Personal Perspective On Victoria’s Stagnant Mental Health System by Dr Eli Kotler

Dr Eli Kotler

When You Trip Upon A Star By Charlotte McAdam

REFERENCES

A Magic Medicine Journey By Tania de Jong AM

Tania de Jong AM

On the Need for a Bioethics of Psychedelic Psychotherapy: A Few Preliminary Challenges By Eddie Jacobs

References

Subscribe to our newsletter